WO2003045391A1 - Pharmaceutical formulations comprising an immune response modifier - Google Patents

Pharmaceutical formulations comprising an immune response modifier Download PDF

Info

Publication number
WO2003045391A1
WO2003045391A1 PCT/US2002/038190 US0238190W WO03045391A1 WO 2003045391 A1 WO2003045391 A1 WO 2003045391A1 US 0238190 W US0238190 W US 0238190W WO 03045391 A1 WO03045391 A1 WO 03045391A1
Authority
WO
WIPO (PCT)
Prior art keywords
imidazo
amine
amines
formulation
alkyl
Prior art date
Application number
PCT/US2002/038190
Other languages
French (fr)
Inventor
Raymond D. Skwierczynski
Terri F. Busch
Amy L. Gust-Heiting
Mary T. Fretland
Matthew T. Scholz
Original Assignee
3M Innovative Properties Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ532769A priority Critical patent/NZ532769A/en
Priority to IL16178602A priority patent/IL161786A0/en
Application filed by 3M Innovative Properties Company filed Critical 3M Innovative Properties Company
Priority to DE60228611T priority patent/DE60228611D1/en
Priority to KR1020047008119A priority patent/KR100962751B1/en
Priority to EP02798470A priority patent/EP1450804B9/en
Priority to BR0214566-9A priority patent/BR0214566A/en
Priority to DK02798470T priority patent/DK1450804T3/en
Priority to MXPA04005023A priority patent/MXPA04005023A/en
Priority to CA2467828A priority patent/CA2467828C/en
Priority to AU2002363954A priority patent/AU2002363954B2/en
Priority to JP2003546893A priority patent/JP4447914B2/en
Publication of WO2003045391A1 publication Critical patent/WO2003045391A1/en
Priority to IL161786A priority patent/IL161786A/en
Priority to HRP20040474AA priority patent/HRP20040474B1/en
Priority to NO20042714A priority patent/NO328298B1/en
Priority to HK05106305.2A priority patent/HK1073778A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Definitions

  • the present invention is directed to pharmaceutical formulations comprising at least one immune response modifier chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines.
  • Embodiments of the present invention are directed to topical formulations for application to the skin of a mammal.
  • Other embodiments of the present invention are directed to methods for treating dermal diseases.
  • imidazoquinoline amine imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazoloquinoline amine, oxazoloquinoline amine, thiazolopyridine amine, oxazolopyridine amine, imidazonaphthyridine amine, imidazotetrahydronaphthyridme amine, and thiazolonaphthyridine amine compounds have demonstrated potent immunostimulating, antiviral and antitumor (including anticancer) activity, and have also been shown to be useful as vaccine adjuvants.
  • IRM immune response modifier
  • IRM compounds The mechanism for the antiviral and antitumor activity of these IRM compounds is thought to be due in substantial part to enhancement of the immune response by induction of various important cytokines (e.g., interferons, interleukins, tumor necrosis factor, etc.).
  • cytokines e.g., interferons, interleukins, tumor necrosis factor, etc.
  • Such compounds have been shown to stimulate a rapid release of certain monocyte/macrophage-derived cytokines and are also capable of stimulating B cells to secrete antibodies which play an important role in these IRM compounds' antiviral and antitumor activities.
  • One of the predominant immunostimulating responses to these compounds is the induction of interferon (IFN)- ⁇ production, which is believed to be very important in the acute antiviral and antitumor activities seen.
  • IFN interferon
  • up regulation of other cytokines such as, for example, tumor necrosis factor (TNF), Interleukin-1 (IL-1) and IL-6 also have potentially beneficial activities and are believed to contribute to the antiviral and antitumor properties of these compounds.
  • TNF tumor necrosis factor
  • IL-1 Interleukin-1
  • IL-6 also have potentially beneficial activities and are believed to contribute to the antiviral and antitumor properties of these compounds.
  • IRMs the ability to provide therapeutic benefit via topical application of an IRM compound for treatment of a particular condition at a particular location may be hindered by a variety of factors. These factors include irritation of the skin to which the formulation is applied, formulation wash away, insolubility and/or degradation of the IRM compound in the formulation, physical instability of the formulation (e.g., separation of components, thickening, precipitation/agglomerization of active ingredient, and the like), poor permeation, and undesired systemic delivery of the topically applied IRM compound. Accordingly, there is a continuing need for new methods and formulations to provide the greatest therapeutic benefit from this class of compounds.
  • the present invention is directed to a pharmaceutical formulation comprising an immune response modifier selected from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms; and a hydrophilic viscosity enhancing agent selected from cellulose ethers and carbomers.
  • the pharmaceutical formulation comprises an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms.
  • an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines
  • a fatty acid and a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms.
  • the formulation can further comprise one or more of a preservative system, an emulsifier, and water.
  • the present invention is directed to a method of treatment of a dermal associated condition comprising applying to skin a topical formulation comprising an immune response modifier selected from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms; and a hydrophilic viscos
  • the method of treatment of a dermal associated condition comprises applying to skin a formulation comprising an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms.
  • an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines
  • a fatty acid and a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms.
  • the method of treatment of a dermal associated condition comprises applying to skin a formulation comprising an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms; and further comprising one or more of a preservative system, an emulsifier, and water.
  • an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines
  • a fatty acid a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms
  • the dermal associated condition is selected from actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts.
  • the present invention is directed to a method for delivering an immune response modifier to a dermal surface, the method comprising the steps of selecting a formulation comprising a compound selected from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazoloquinoline amines, oxazolo-quinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a
  • the selected formulation comprises an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms.
  • an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines
  • a fatty acid and a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms.
  • the present invention is directed to a fonnulation comprising an immune response modifier compound selected from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms, and a hydrophilic viscosity enhancing agent selected from cellulose ethers and carbo
  • the IRM compound can be chosen from imidazoquinoline amines, for example, lH-imidazo[4,5-c]quinolin-4-amines defined by one of Formulas I-V below:
  • R ⁇ is chosen from alkyl of one to ten carbon atoms, hydroxyalkyl of one to six carbon atoms, acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms, benzyl, (phenyl)ethyl and phenyl, said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that if said benzene ring is substituted by two of said moieties, then said moieties together contain no more than six carbon atoms;
  • R 21 is chosen from hydrogen, alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that when the benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and each Ri is independently chosen from alkoxy of one to four carbon atoms, halogen, and alkyl of one to four carbon atoms, and n is an integer from 0 to 2, with the proviso that if n is 2, then said R ⁇ groups together contain no more than six carbon atoms;
  • R 12 is chosen from straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is chosen from straight chain or branched chain alkyl containing one to four carbon atoms and cycloalkyl containing three to six carbon atoms; and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; and
  • R 2 is chosen from hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently chosen from straight chain or branched chain alkyl containing one to four carbon atoms, straight chain or branched chain alkoxy containing one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and each R 2 is independently chosen from straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said
  • R 23 is chosen from hydrogen, straight chain or branched chain alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently chosen from straight chain or branched chain alkyl of one to four carbon atoms, straight chain or branched chain alkoxy of one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and each R 3 is independently chosen from straight chain or branched chain alkoxy of one to four carbon atoms, halogen, and straight chain or branched chain alkyl of one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R 3
  • R 14 is -CHR x R y wherein R y is hydrogen or a carbon-carbon bond, with the proviso that when R y is hydrogen R x is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1 -alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, or 2-, 3-, or 4-pyridyl, and with the further proviso that when R y is a carbon-carbon bond R y and R x together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently chosen from hydroxy and hydroxyalkyl of one to four carbon atoms;
  • R 24 is chosen from hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen; and is chosen from hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms;
  • R 15 is chosen from: hydrogen; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is chosen from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is chosen from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to
  • Rs and R ⁇ are independently chosen from hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen;
  • X is chosen from alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, chloro, hydroxy, 1-morpholino, 1-pyrrolidino, alkylthio of one to four carbon atoms; and
  • R 5 is chosen from hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms; and a pharmaceutically acceptable salt of any of the foregoing.
  • the IRM compound can also be chosen from 6,7 fused cycloalkylimidazopyridine amines defined by Formula VI below:
  • n 1, 2, or 3;
  • R ⁇ 6 is chosen from hydrogen; cyclic alkyl of tliree, four, or five carbon atoms; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is chosen from cycloalkyl containing tliree to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; fluoro- or chloroalkyl containing from one to ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is chosen from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to
  • R y is hydrogen or a carbon-carbon bond, with the proviso that when R y is hydrogen R x is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1- alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, or 2-, 3-, or 4-pyridyl, and with the further proviso that when R y is a carbon-carbon bond R y and R x together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently chosen from hydroxy and hydroxyalkyl of one to four carbon atoms,
  • R 26 is chosen from hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, straight chain or branched chain hydroxyalkyl containing one to six carbon atoms, morpholinoalkyl, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by a moiety chosen from methyl, methoxy, and halogen; and
  • R ⁇ are independently chosen from hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen;
  • X is chosen from alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, alkylthio of one to four carbon atoms, and morpholinoalkyl wherein the alkyl moiety contains one to four carbon atoms, and
  • R 6 is chosen from hydrogen, fiuoro, chloro, straight chain or branched chain alkyl containing one to four carbon atoms, and straight chain or branched chain fiuoro- or chloroalkyl containing one to four carbon atoms and at least one fluorine or chlorine atom; and pharmaceutically acceptable salts thereof.
  • the LRM compound can be chosen from imidazopyridine amines defined by Formula VII below:
  • R 27 is chosen from hydrogen; straight chain or branched chain alkyl containing one to eight carbon atoms; straight chain or branched chain hydroxyalkyl containing one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl oand phenyl being optionally substituted on the benzene ring by a moiety chosen from methyl, methoxy, and halogen; and morpholinoalkyl wherein the alkyl moiety contains one to four carbon atoms;
  • R 67 and R 77 are independently chosen from hydrogen and alkyl of one to five carbon atoms, with the proviso that R 67 and R 77 taken together contain no more than six carbon atoms, and with the further proviso that when R is hydrogen then R 6 is other than hydrogen and R 27 is other than hydrogen or morpholinoalkyl, and with the further proviso that when R 6 is hydrogen then R 7 and R 27 are other than hydrogen; and pha riaceutically acceptable salts thereof.
  • the IRM compound can be chosen from 1,2-bridged imidazoquinoline amines defined by Formula VIII below:
  • Z is chosen from: -(CH 2 ) P - wherein p is 1 to 4;
  • R D is hydrogen or alkyl of one to four carbon atoms
  • RE is chosen from alkyl of one to four carbon atoms, hydroxy, -OR F wherein Rp is alkyl of one to four carbon atoms, and -NRQR' G wherein R G and R' G are independently hydrogen or alkyl of one to four carbon atoms;
  • the IRM compound can be chosen from thiazoloquinoline amines, oxazoloquinoline amines, thiazolonaphthyridine amines, thiazolopyridine amines, and oxazolopyridine amines of Formula IX:
  • R 19 is chosen from oxygen, sulfur and selenium;
  • R 29 is chosen from -hydrogen;
  • R 39 and r ⁇ are each independently:
  • R 39 and R 49 form a fused aromatic, heteroaromatic, cycloalkyl or heterocyclic ring;
  • X is chosen from -O-, -S-, -NR 59 - -C(O)-, -C(O)O- -OC(O)-, and a bond; and each R 59 is independently H or C ⁇ -8 alkyl; and pharmaceutically acceptable salts thereof.
  • the IRM compound can be chosen from imidazonaphthyridine amines and imidazotetrahydronaphthyridme amines of Formulae X and XI below:
  • R ⁇ o is chosen from:
  • Y is -N- or -CR-;
  • R 21 o is chosen from: -hydrogen; -CLIO alkyl; -C 2-10 alkenyl;
  • each R 31 o is independently chosen from hydrogen and CM O alkyl; and each R is independently chosen from hydrogen, C 1-10 alkyl, C MO alkoxy, halogen and trifluoromethyl, and pharmaceutically acceptable salts thereof;
  • Ri ⁇ is chosen from: - hydrogen; -Ci.2 0 alkyl or C2 -2 o alkenyl that is unsubstituted or substituted by one or more substituents chosen from: -aryl;
  • Y is -N- or -CR-; hosen from: -hydrogen; -Ci-io alkyl;
  • each R 3 ⁇ is independently chosen from hydrogen and C 1-10 alkyl; and each R is independently chosen from hydrogen, C 1-10 alkyl, C 1-10 alkoxy, halogen and trifiuoromethyl, and pharmaceutically acceptable salts thereof.
  • the IRM compound can be chosen from imidazoquinoline amines and imidazotetrahydroquinoline amines, for example, lH-imidazo[4,5-c]quinolin- 4-amines and tetrahydro-lH-imidazo[4,5-c]quinolin-4-amines defined by Formulas XII, XIII and XIV below:
  • R 112 is -alkyl-NR 31 2-CO-R 412 or -alkenyl-NR 3 ⁇ 2 -CO- R ⁇ wherein u 2 is aryl, heteroaryl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents chosen from: -alkyl;
  • R 212 is chosen from: -hydrogen; -alkyl; -alkenyl;
  • each R312 is independently chosen from hydrogen; C MO alkyl-heteroaryl; C MO alkyl-(substituted heteroaryl); C 1-10 alkyl-aryl; C 1-10 allcyl-(substituted aryl) and C 1-10 alkyl; v is 0 to 4; and each R 12 present is independently chosen from C 1-10 alkyl, .io alkoxy, halogen and trifluoromethyl;
  • R ⁇ 3 is -alkyl-NR 313 - SO 2 -X-R413 or -alkenyl-NR 313 - SO 2 -X-R413 ;
  • X is a bond or -NR 513 -;
  • R 413 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents chosen from:
  • R is alkyl, alkenyl, or heterocyclyl, oxo; chosen from:
  • each R 313 is independently chosen from hydrogen, C 1- 0 alkyl, and when X is a bond R 313 and Rn 3 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring;
  • R 513 is chosen from hydrogen, C M0 alkyl, and u 3 and R 513 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring; v is 0 to 4 and each R ⁇ 3 present is independently chosen from C 1-10 alkyl, C O alkoxy, halogen and trifluoromethyl;
  • R 114 is -alkyl-NR3i4-CY-NR5i4-X-R4i4 or -alkenyl-NR 314 -CY- NR514-X- 414 wherein
  • X is a bond, -CO- or -SO 2 -
  • t is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents chosen from:
  • R 4 ⁇ is alkyl, alkenyl or heterocyclyl, oxo; with the proviso that when X is a bond Ru 4 can additionally be hydrogen;
  • R 2 i4 is chosen from:
  • each R 314 is independently chosen from hydrogen and C O alkyl
  • Rs 1 is chosen from hydrogen, Ci-io alkyl, and R 414 and R5 14 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring
  • v is 0 to 4 and each R 1 present is independently chosen from Cno alkyl, C 1-10 alkoxy, halogen and trifluoromethyl, and pharmaceutically acceptable salts thereof.
  • the IRM compound can be chosen from imidazoquinoline amines and imidazotetrahydroquinoline amines, for example, ⁇ H- imidazo[4,5-c]quinolin-4-amines and tetrahydro- lH-imidazo[4,5-c]quinolin-4-amines defined by Formulas XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, and XXVI below
  • X is -CHR 5 ⁇ 5 -, -CHR 515 -alkyl-, or -CHR 515 -alkenyl-;
  • Rn 5 is chosen from:
  • R 2 i 5 is chosen from:
  • n ⁇ is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R ⁇ t s is independently H or Ci-io alkyl;
  • R 6!5 is a bond, alkyl, or alkenyl, which may be interrupted by one or more -O- groups;
  • R ⁇ s is H, C MO alkyl, arylalkyl, or R 415 and R 715 can join together to form a 5 to 7 membered heterocylcic ring;
  • Rsi 5 is H, Ci-io alkyl, or R 15 and R 8 ⁇ 5 can join together to form a 5 to 7 membered heterocyclic ring;
  • Y is -O- or -S(O) 0-2 -;
  • v is 0 to 4; and each R 15 present is independently chosen from CM O alkyl, .io alkoxy, hydroxy, halogen and trifluoromethyl;
  • X is -CHR 516 -, -CHR 516 -alkyl-, or -CHR 516 -alkenyl-;
  • Rue is chosen from:
  • R 216 is chosen from: -hydrogen;
  • R416 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R 5!6 is independently H or C O alkyl;
  • R6 16 is a bond, alkyl, or alkenyl, which may be interrupted by one or more -O- groups;
  • R 16 is H, C I - IO alkyl, arylalkyl, or R 4K5 and R 16 can join together to form a 5 to 7 membered hetercyclic ring;
  • R 716 and R 816 can join together to form a 5 to 7 membered heterocyclic ring;
  • Y is -O- or -S(O) 0-2 -;
  • v is 0 to 4; and each R 16 present is independently chosen from . 10 alkyl, CM O alkoxy, hydroxy, halogen, and trifluoromethyl;
  • X is -CHR 317 -, -CHR 317 -alkyl-, or -CHR 317 -alkenyl-; R is chosen from:
  • R 217 is chosen from: -hydrogen;
  • R t17 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R 3 ⁇ is independently H or C 1-10 alkyl; each Y is independently -O- or -S(O)o-2-; v is 0 to 4; and each R 1 present is independently chosen from C MO alkyl, C O alkoxy, hydroxy, halogen and trifluoromethyl;
  • X is -CHR 318 -, -CHR 318 -alkyl-, or -CHR 318 -alkenyl-;
  • R ⁇ s is chosen from:
  • R 2 i 8 is chosen from:
  • R 418 is alkyl or alkenyl, which may be interrupted by one or more
  • X is -CHR 319 -, -CHR 3 ⁇ -alkyl-, or -CHR 319 -alkenyl-;
  • Ri 19 is chosen from: -heteroaryl; -heterocyclyl; -R 419 - heteroaryl; and -R 41 -heterocyclyl; R 219 is chosen from: -hydrogen; -alkyl;
  • t!9 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each Rj 19 is independently H or C MO alkyl; each Y is independently -O- or -S(O)o-2-; v is 0 to 4; and each R 19 present is independently chosen from C 1-10 alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl;
  • X is -CHR 320 -, -CHR 32 o-alkyl-, or -CHR 32 o-alkenyl-;
  • Ri 2 o is chosen from: -heteroaryl; -heterocyclyl;
  • R 22 o is chosen from: -hydrogen; -alkyl;
  • R 420 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R3 2 0 is independently H or CMO alkyl; each Y is independently -O- or -S(O)o- 2 S v is 0 to 4; and each R 20 present is independently chosen from CMO alkyl, CMO alkoxy, hydroxy, halogen and rrifluoromethyl;
  • X is -CHR 521 -, -CHR 52 ⁇ -alkyl-, or -CHR 521 -alkenyl-;
  • R 12 ⁇ is chosen from:
  • -R4 — NR 321 — SO 2 — R ⁇ 521 — alkyl; -R4: — NR 32 ⁇ — SO 2 — 6 21 — alkenyl; -Rt: -NR 321 -SO 2 -R 62 i-aryl; -R4: -NR 321 -SO 2 -R 621 -heteroaryl; -R4 -NR 321 -SO 2 -R 621 -heterocyclyl; -R4: — NR 321 — SO 2 — R72U -R4: -NR 32 i-SO 2 -NR 521 -R 62 ⁇ -alkyl; -R4: -NR 321 -SO 2 -NR 52 i-R 62 i-alkenyl; -R4: -NR 321 -SO 2 -NR 52 i-R 62 i-aryl; -R 42 i-NR 32
  • Y is -O- or -S(O)o -2 -;
  • R 321 is H, C 1-10 alkyl, or arylalkyl; each R 421 is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups, or R 321 and R 421 can join together to form a 5 to 7 membered heterocyclic ring;
  • each Rs 2 i is independently H, CMO alkyl, or C 2-10 alkenyl;
  • Re 2 i is a bond, alkyl, or alkenyl, which may be interrupted by one or more -
  • R 72 ⁇ is CMO alkyl, or R 32 ⁇ and R 21 can join together to fonn a 5 to 7 membered heterocyclic ring; v is 0 to 4; and each R 21 present is independently chosen from C O alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl;
  • X is -CHR 522 -, -CHR 522 -alkyl-, or -CHR 522 -alkenyl-;
  • R122 is chosen from: -R422—NR322—SO2—R622— alkyl;
  • R222 is chosen from: -hydrogen; -alkyl; -alkenyl; -aryl; -R 422 -NR 322 -SO 2 -NR 522 -R 622 -aryl; -R 422 -NR 322 -SO2-NR522-R 622 -heteroaryl; -R 422 -NR 322 -S ⁇ 2-NR 52 2-R 6 2 2 -heterocyclyl; and R222 is chosen from: -hydrogen; -alkyl; -alkenyl; -aryl;
  • each R_j 22 is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups, or R 322 and R 22 can join together to fonn a 5 to 7 membered heterocyclic ring; each R 522 is independently H, C MO alkyl, or C 2-10 alkenyl; R6 22 is a bond, alkyl, or alkenyl, which may be interrupted by one or more - O- groups; R 722 is C MO alkyl, or R 322 and R 72 can join together to form a 5 to 7 membered heterocyclic ring; v is 0 to 4; and each R 22 present is independently chosen from C MO alkyl, CMO alkoxy, hydroxy, halogen, and trifluoromethyl;
  • X is -CHR 323 -, -CHR 323 -alkyl-, or -CHR 323 -alkenyl-;
  • Z is -S-, -SO-, or-SO 2 -;
  • R 123 is chosen from: -alkyl;
  • R 223 is chosen from: -hydrogen; -alkyl;
  • each Rj 23 is independently H or C MO alkyl; each j 23 is independently alkyl or alkenyl; each Y is independently -O- or -S(O)o -2 -; v is 0 to 4; and each R 23 present is independently chosen from C MO alkyl, C MO alkoxy, hydroxy, halogen and trifluoromethyl;
  • X is -CHR 324 -, -CHR 324 -alkyl-, or -CHR 324 -alkenyl-;
  • Z is -S-, -SO-, or -SO 2 -;
  • R124 is chosen from:
  • R 22 4 is chosen from:
  • each R 324 is independently H or C MO alkyl; each R424 is independently alkyl or alkenyl; each Y is independently -O- or -S(O) 0-2 -; v is 0 to 4; and each R 24 present is independently chosen from CMO alkyl, C O alkoxy, hydroxy, halogen and trifluoromethyl;
  • X is -CHR 25 -, -CHR 525 -alkyl-, or -CHR 525 -alkenyl-;
  • R 125 is chosen from:
  • R 225 is chosen from:
  • each Rj 2 s is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R 525 is independently H or C O alkyl;
  • R f i 25 is a bond, alkyl, or alkenyl, which may be interrupted by one or more -O- groups;
  • R 25 is H, C MO alkyl which may be interrupted by a hetero atom, or R 725 can join with R 525 to form a 5 to 7 membered heterocyclic ring;
  • Rs25 is H, C MO alkyl, arylalkyl, or R4 25 and R 825 can join together to form a 5 to 7 membered heterocyclic ring;
  • R 92 5 is C MO alkyl which can join together with R 825 to form a 5 to 7 membered heterocyclic ring;
  • each Y is independently -O- or -S(O)o-2-;
  • Z is a bond, -CO- or -SO2-;
  • v is 0 to 4; and each R2 5 present is independently chosen from C MO alkyl, C O alkoxy, hydroxy, halogen and triffuoromethyl;
  • X is -CHR 526 -, -CHR 526 -alkyl-, or -CHR 526 -alkenyl-;
  • R 12 6 is chosen from:
  • R 226 is chosen from:
  • R 626 is a bond, alkyl, or alkenyl, which may be interrupted by one or more -O- groups;
  • R 726 is H, C O alkyl which may be interrupted by a hetero atom, or R 726 can join with R 526 to form a 5 to 7 membered heterocyclic ring;
  • Rg 26 is H, C O alkyl, arylalkyl, or R 426 and R 826 can join together to form a
  • R 926 is C MO alkyl which can join together with R 826 to fonn a 5 to 7 membered heterocyclic ring; each Y is independently -O- or -S(O)o- 2 -; Z is a bond, -CO- or -SO 2 -; v is 0 to 4; and each R 26 present is independently chosen from C MO alkyl, C MO alkoxy, hydroxy, halogen, and trifluoromethyl; and pharmaceutically acceptable salts of any of the foregoing.
  • the IRM compound can be chosen from lH-imidazo[4,5- c]pyridin-4-amines compounds defined by Formula XXVII
  • X is alkylene or alkenylene
  • Y is -CO- -CS-, or -SO 2 -
  • Z is a bond, -O-, -S-, or -NR 52 -;
  • R 127 is aryl, heteroaryl, heterocyclyl, C MO alkyl or C 2-2 o alkenyl, each of which may be unsubstituted or substituted by one or more substituents independently chosen from: -alkyl;
  • -alkyl-S ⁇ aryl -alkyl-O- alkenyl; -alkyl-S- alkenyl; and
  • R 327 and 427 are independently chosen from hydrogen, alkyl, alkenyl, halogen, alkoxy, amino, alkylamino, dialkylamino and alkylthio; each R 527 is independently H or C M oalkyl; and pharmaceutically acceptable salts thereof.
  • alkyl alkenyl
  • alk- alk-
  • these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms.
  • Preferred groups have a total of up to 10 carbon atoms.
  • Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms.
  • Exemplary cyclic groups include cyclopropyl, cyclopropylmefhyl, cyclopentyl, cyclohexyl and adamantyl.
  • haloalkyl is inclusive of groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of groups that include the prefix "halo-”. Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.
  • aryl as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl.
  • heteroaryl includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N).
  • Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, and so on.
  • Heterocyclyl includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N) and includes all of the fully saturated and partially unsaturated derivatives of the above mentioned heteroaryl groups.
  • exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, fhiazolidinyl, imidazolidinyl, isothiazolidinyl, and the like.
  • the topical formulations of the present invention are prepared using the free base form of the IRM compound.
  • the amount of an IRM compound that will be therapeutically effective in a specific situation will depend on such things as the activity of the particular compound, the dosing regimen, the application site, the particular formulation and the condition being treated. As such, it is generally not practical to identify specific administration amounts herein; however, those skilled in the art will be able to determine appropriate therapeutically effective amounts based on the guidance provided herein, information available in the art pertaining to these compounds, and routine testing.
  • a therapeutically effective amount means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, inhibition of TH2 immune response, antiviral or antitumor activity, reduction or elimination of postsurgical scarring, or reduction or resolution of actinic keratosis or pre- actinic keratosis lesions.
  • the amount of the IRM compound present in a topical formulation of the invention will be an amount effective to treat a targeted condition, to prevent recurrence of the condition, or to promote immunity against the condition.
  • the amount or concentration of the IRM compound can range from 0.001%) to 10% by weight based on the total formulation weight, such as, for example, from 0.03% > to 5.0%> by weight, or from
  • the amount of the IRM compound is at least 0.003%o by weight, such as, for example, at least 0.005%, at least 0.01%o, at least 0.03%, at least 0.10% > , at least 0.30%> and at least 1.0%. In other embodiments, the amount of the IRM compound is at most 5.0%> by weight, such as, for example, at most 3.0%, and at most 1.0%.
  • the topical formulations of the invention additionally comprise a fatty acid.
  • fatty acid means a carboxylic acid, either saturated or unsaturated, comprising 6 to 28 carbon atoms, such as, for example, from 10 to 22 carbon atoms.
  • Non-limiting examples of such fatty acids include isostearic acid, oleic acid, and linear- or- branched chained carboxylic acids of 6 to 18 carbon atoms.
  • the fatty acid may be present in the formulation in an amount sufficient to solubilize the IRM compound.
  • the amount of the fatty acid can range from 0.05 %> to 40 % by weight based on the total weight of the formulation, such as, for example, from 1% to 30%, from 3%» to 15%o and from 5% to 10%. In certain embodiments, the amount of the fatty acid is at least 3.0%o by weight, such as, for example, at least 5.0%, at least 10.0%>, and at least 25%.
  • the fatty acid component of the formulation can comprise one or more fatty acids.
  • the topical formulations of the invention additionally comprise at least one hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms.
  • hydrophobic is meant that the component is essentially insoluble in water, i.e. immiscible with water and unable to form a micelle in water, and does not contain polyoxyethylene or acid salt groups.
  • aprotic component has a hydrophilic lipophilic balance (HLB) of less than 2.
  • the HLB of a component maybe determined as described, for example, in Attwood, D., Florence, A. T. Surfactant Systems: Their Chemistry, Pharmacy, and Biology. New York: Chapman & Hall, 471-473, 1983.
  • aprotic is meant that the component cannot donate a proton to the IRM and does not contain groups such as carboxyl, hydroxy, primary and secondary amino, primary and secondary amido, or quaternary ammonium groups.
  • this component has a pKa of at least 14.2 and does not substantially solubilize or form a complex such as an acid-base pair or complex or a hydrogen bond complex with the IRM compound.
  • a complex such as an acid-base pair or complex or a hydrogen bond complex with the IRM compound.
  • not substantially is meant that the ratio of the IRM compound's solubility in the hydrophilic, aprotic component to that in isostearic acid is less than 1 :40.
  • Formulations intended for dermal or topical use desirably have a certain minimum amount of an oil phase to provide qualities such as spreadability, feel on the skin, texture, and so on. However, if all the components of the oil phase solubilize the IRM, then the degree of saturation of the IRM in the formulation will decrease, making it more difficult to deliver the IRM from the formulation to the skin.
  • Addition of the hydrophobic, aprotic component can increase the oil phase volume of the topical formulation to provide desirable qualitites such as spreadability and feel, while at the same time not appreciably altering the degree of saturation or thermodynamic activity of the IRM.
  • the amount of fatty acid, which solubilizes the IRM can be reduced to increase the degree of IRM saturation while maintaining a sufficient oil phase volume by virtue of the addition of the hydrophobic, aprotic component, which does not offset the increased IRM saturation.
  • the topical formulation of the present invention can facilitate both physical property and drug delivery requirements. Degree of saturation and thermodynamic activity of the
  • IRM in these formulations is equal to the IRM concentration in the oil phase divided by the saturation concentration of the IRM in the oil phase.
  • the thermodynamic activity or degree of saturation is unity, and when partially saturated the thermodynamic activity or degree of saturation is less than unity.
  • the amount of the hydrophobic, aprotic component present in a formulation of the invention can range from 1% to 30% by weight based on the total formulation weight, for example, from 3 % to 15%> by weight, and from 5 to 10%> by weight, hi certain embodiments, the amount of the hydrophobic, aprotic component is at least 3.0%> by weight, for example, at least 5.0%>, and at least 10.0%>.
  • the weight ratio of the hydrophobic, aprotic component to the fatty acid can be 0.025:1 to 600:1, for example, 0.5:1 to 50:1, and 2:1 to 30:1.
  • the combined amount (weight percent of the total topical formulation weight) of the hydrophobic, aprotic component and the fatty acid can be 2% to 50% by weight, for example 2% to 30%, 5% to 30%, 5% to 20%, and 10% to 20%.
  • useful hydrophobic, aprotic components include but are not limited to fatty acid esters, for example, isopropyl mysristate, isopropyl palmitate, diisopropyl dimer dilinoleate; triglycerides, for example, caprylic/capric triglyceride; cetyl esters wax; hydrocarbons of 8 or more carbon atoms, for example, light mineral oil, white petrolatum; and waxes, for example, beeswax.
  • the hydrophobic, aprotic component is chosen from one or more of isopropyl mysristate, isopropyl palmitate, caprylic/capric triglyceride, and diisopropyl dimer dilinoleate.
  • the formulations of the present invention can also comprise a hydrophilic viscosity enhancing agent.
  • suitable hydrophilic viscosity enhancing agents include cellulose ethers such as hydroxypropylmethylcellulose, hydroxyefhylcelfulose, hydroxypropylcellulose, and carboxymethylcellulose; polysaccharide gums such as xanthan gum; and homopolymers and copolymers of acrylic acid crosslinked with allyl sucrose or allyl pentaerythriol such as those polymers designated as carbomers in the United States Pharmacopoeia.
  • Suitable carbomers include, for example, those available as CarbopolTM 934P, Carbopol 97 IP, Carbopol 940, Carbopol 974P, Carbopol 980, and PemulenTM TR-1 (USP/NF Monograph; Carbomer 1342), all available from Noveon, Cleveland, Ohio.
  • the viscosity enhancing agent is chosen from Carbopol 974P and 980.
  • the viscosity enhancing agent is generally present in an amount ranging from 0.1 %> to 10%> by weight of total formulation weight, such as, for example, from 0.5 %> to 5%> by weight, from 0.5%> to 1.5% by weight, and from 0.7%) to 3%> by weight.
  • the amount of the viscosity enhancing agent is at least 0.5%o by weight, for example, at least 0.6% by weight, at least 0.7%> by weight, at least 0.9%> by weight, and at least 1.0% by weight.
  • the formulations of the invention can additionally comprise an emulsifier.
  • Suitable emulsifiers include non-ionic surfactants such as, for example, polysorbate 60, sorbitan monostearate, polyglyceryl-4 oleate, polyoxyethylene(4) lauryl ether, etc.
  • the emulsifier is chosen from poloxamers (e.g., PluronicTM F68, also known as Poloxamer 188, a poly(ethylene glycol)-block-poly(propylene glycol)-block- poly(ethylene glycol), available from BASF, Ludwigshafen, Germany) and sorbitan trioleate (e.g., Span 85 available from Uniqema, New Castle, DE).
  • the emulsifier is generally present in an amount of 0.1%o to 10%o by weight of total formulation weight, for example, from 0.5%> to 5%> by weight, and from 0.75%) to 3.5%> by weight. In certain embodiments, the amount of the emulsifier is at least 1.0% by weight, for example, at least 2.5%, at least 3.5%, and at least 5.0%>.
  • the formulation can also include at least one chelating agent.
  • the chelating agent functions to chelate metal ions that may be present in the formulation. Suitable chelating agents include salts of ethylenediaminetetraacetate (EDTA), such as the disodium salt. If included, the chelating agent is generally present in an amount ranging from 0.001 % to 0.1% by weight, and preferably from 0.01% to 0.05%) by weight. In certain embodiments, the amount of the chelating agent is at least 0.005% > by weight, such as, for example, at least 0.01%, and at least 0.05%.
  • the formulation can also include a preservative system.
  • the preservative system is generally comprised of at least one preservative compound chosen from methylparaben, ethylparaben, propylparaben, phenoxyethanol, iodopropynyl butylcarbamate, sorbic acid, a fatty acid monoester of glycerin such as glycerol monolaurate, and a fatty acid monoester of propylene glycol such as propylene glycol monocaprylate.
  • the preservative system may also include a preservative enhancing solubilizer which enhances the solubility of the preservative in the aqueous phase, examples of which include diethylene glycol monoethyl ether and propylene glycol.
  • the preservative system can be comprised of methylparaben, propylparaben, and propylene glycol. In another embodiment, the preservative system can be comprised of methylparaben, ethylparaben, and diethylene glycol monoethyl ether. In one embodiment, the preservative system can be comprised of phenoxyethanol, methylparaben or methyl- and ethylparaben, and diethylene glycol monoethyl ether. In another embodiment, the preservative system can be comprised of iodopropynyl butylcarbamate.
  • the preservative system can be comprised of iodopropynyl butylcarbamate, diethylene glycol monoethyl ether, and poly( ethylene glycol)(4) monolaurate.
  • the preservative system can be comprised of iodopropynyl butylcarbamate, one or more of methylparaben, ethylparaben, propylparaben, or phenoxyethanol, and diethylene glycol monoethyl ether.
  • the methylparaben, ethylparaben, and propylparaben can each be present in the formulations in an amount ranging from 0.01% to 0.5% by weight of the formulation weight, for example, from 0.05 %> to 0.25%> by weight, and from 0.1%o to 0.2% by weight.
  • the iodopropynyl butylcarbamate can be present in the formulations in an amount ranging from 0.01% to 0.1%.
  • the phenoxyethanol can be present in the formulations in an amount ranging from 0.1% to 1%>.
  • the propylene glycol and diethylene glycol monoethyl ether can each be present in the formulations in an amount ranging from 1% to 30%o by weight of the formulation weight, such as, for example, from 5 % to 25%o by weight, and from 10%> to 15%> by weight.
  • the preservative system can be present in the formulations in an amount ranging from 0.01%> to 30%> by weight of the formulation weight, for example, from 0.05% to 30%), from 0.1%> to 25%o by weight, and from 0.2%o to 15%) by weight.
  • the methylparaben, ethylparaben, propylparaben, iodopropynyl butylcarbamate, and phenoxyethanol can be solubilized in propylene glycol, poly(ethylene glycol)(4) monolaurate, or diethylene glycol monoethyl ether prior to addition to the formulation.
  • the preservative system can be selected such that it meets the criteria for antimicrobial effectiveness set forth in the United States Pharmacopeia ⁇ 51>.
  • the formulations of the present invention may additionally comprise at least one pH adjuster. Suitable pH adjusters include organic bases and inorganic bases such as, for example, KOH, NaOH.
  • the pH of the topical formulations of the present invention generally ranges from 3.5 to 7.0. In one embodiment, the pH of the topical formulations of the present invention can range from 4.0 to 6.0, preferably 5.0. In another embodiment of the invention, the pH of the topical formulations of the present invention can range from 5.5 to 6.5, preferably 6.0.
  • any of the foregoing formulations can be in the form of an oil-in- water emulsion such as a cream or a lotion.
  • Such an emulsion can comprise an oil phase comprising the IRM compounds, a fatty acid in an amount sufficient to solubilize the IRM compounds, a hydrophobic, aprotic component; and an aqueous phase comprising a hydrophilic viscosity enhancing agent, for example, a carbomer.
  • the amount or concentration of the IRM in the oil phase can be at least 0.01%>, for example, at least 0.02%), at least 0.1 %>, and at least 1% with respect to oil phase weight. In other embodiments, the amount or concentration of the IRM in the oil phase can be at most
  • any of the foregoing formulations according to the present invention can be applied to the dermal surfaces of a mammal.
  • the therapeutic effect of the IRM compound may extend only to the superficial layers of the dermal surface or to tissues below the beal surface.
  • another aspect of the present invention is directed to a method for the treatment of a dermal associated condition comprising applying to skin one of the foregoing formulations.
  • a "dermal associated condition” means an inflammatory, infectious, neoplastic or other condition that involves a dermal surface or that is in sufficient proximity to a dermal surface to be affected by a therapeutic agent topically applied to the dermal surface.
  • a dermal associated condition include warts, atopic dermatitis, basal cell carcinoma, postsurgical scars, and actinic keratosis.
  • the formulations can be applied to the surface of skin for treatment of actinic keratosis (AK).
  • Actinic keratoses are premalignant lesions considered biologically to be either carcinoma in-situ or squamous intraepidennal neoplasia.
  • AK is the most frequent epidermal tumor and is induced by ultraviolet (UV) radiation, typically from sunlight. Because of its precancerous nature, AK may be considered the most important manifestation of sun-induced skin damage.
  • the above described formulations are particularly advantageous for dermal application for a period of time sufficient to obtain a desired therapeutic effect without undesired systemic absorption of the IRM.
  • Examples 1-7 and Comparative Example CI Table 1 summarizes topical formulations made in accordance with the present invention in a percentage weight-by-weight basis.
  • Methylparaben and propylparaben were dissolved in propylene glycol and the solution was subsequently added to the water phase. Poloxamer 188 was then added to the water phase and mixed until dissolved.
  • Phase combination The oil phase was added to the water phase at ambient conditions. The emulsion was then homogenized. After homogenization, sodium hydroxide solution
  • Formulations containing 2-methyl-l -(2-methylpropyl)-lH-imidazo[4,5-c] [l,5]naphthyridin-4-amine were tested for their ability to induce increases in cytokine concentrations in rats following topical application. This study was undertaken to evaluate cytokine induction following a single dosing of various strengths and timepoints or a multiple vs. single dosing of IRM Compound 1. The formulations described above were tested by examining tissue and serum concentrations of TNF- ⁇ , MCP-1 (monocyte chemoattractant protein- 1) and IFN- ⁇ cytokines following drug treatment.
  • mice Female CD hairless rats (Charles River Laboratories, Wilmington, MA) weighing 200-250 grams were used in all studies. Animals were randomized to treatment groups and dosed five per treatment group.
  • the rats were acclimated to collars around the neck on two consecutive days prior to actual dosing.
  • the rats were collared before dosing to prevent ingestion of the drug, and were then dosed topically with 50 ⁇ L of active cream or the appropriate placebo on right flank and then housed individually following dosing.
  • the rats were anesthetized and blood was collected by cardiac puncture. Blood was allowed to clot at room temperature and serum was separated from the clot via centrifugation and stored at -20 °C until it was analyzed for cytokine concentrations. Following blood collection, the rats were euthanized and their skins removed.
  • Tissue from both treated site (at) and contralateral site (away) were obtained using an 8 mm punch biopsy, weighed, placed in a sealed 1.8 ml cryovial and flash frozen in liquid nitrogen.
  • the frozen tissue sample was then suspended in 1.0 mL RPMI medium (Celox, Hopkins, MN) containing 10%> fetal bovine serum (Sigma, St. Louis, MO), 2 mM L-glutamine, penicillin streptomycin, and 2-mercaptoethanol (RPMI complete) combined with a protease inhibitor cocktail set III (Calbiochem, San Diego, CA).
  • the tissue was homogenized using a Tissue TearorTM (Biospec Products, Bartlesville, OK) for approximately 1 minute.
  • the tissue suspension was then centrifuged at 2000 rpm for 10 minutes under refrigeration to pellet debris, and the supernatant collected and stored at -20 °C until analyzed for cytokine concentrations.
  • ELISAs for rat MCP-1 were purchased from BioSource Intl. (Camarillo, CA) and rat TNF- ⁇ were purchased from BD Pharmingen (San Diego, CA) and performed according to manufacturer's specifications. Results for both TNF- ⁇ , and MCP-1 were expressed in pg/200 mg tissue or pg/ml serum. The sensitivity of the TNF- ⁇ ELISA was 31.2 pg/ml and of the
  • MCP-1 ELISA was 11.7 pg/ml.
  • IFN- ⁇ concentrations in both serum and skin tissue were determined using a bioassay that measured inhibition of the viral cytopathic effect of vesicular stomatitis virus on rat LMS-C2 fibroblast cells as previously described (Reiter, M. J., Testennan, T. L., Miller, R. L., Weeks, C. E., and Tomai, M. A. (1994) "Cytokine Induction in Mice by the Immunomodulator Imiquimod.” J. Leukocyte Biol. 55, 234-240).
  • results for IFN- ⁇ concentrations were normalized to a standard reference rat IFN- ⁇ , preparation with results being reported in U/mL and are normalized per mg of tissue.
  • Tables 2-4 The data shown below in Tables 2-4 are from three separate experiments and analyzed to 1) measure pharmacokinetics by full time course, 2) measure dose response and 3) measure multiple vs. single dosing.
  • the data are presented in Table 2.
  • a Female hairless CD rats were dosed topically with cream formulated Compound 1.
  • b TNF- ⁇ and MCP-1 were measured by ELISA.
  • IFN- ⁇ was measured by bioassay. Results are presented in pg/ml for serum samples and pg/200 mg tissue for tissue samples and represent the mean of five animals + SEM.
  • a Female hairless CD rats were dosed topically with cream formulated Compound 1.
  • b MCP-1 was measured by ELISA. Results are presented in pg/ml for serum samples and pg/200 mg tissue for tissue samples and represent the mean of five animals + SEM. °Indicates p ⁇ 0.05 when compared to either placebo for serum samples or the difference between treated tissue and control tissue from the same animal.
  • a dose response study (Study 3 with results shown in Table 4) was perfonned by dosing with the topical cream formulations of Examples 3-5 and 7, containing various concentrations of IRM Compound 1. Serum and tissue samples were taken at 8 and 24 hours post dose and analyzed for MCP-1. The studies tested topical delivery of creams comprising IRM Compound 1 for its ability to affect a local MCP-1 induction at four concentrations.
  • MCP-1 was measured by ELISA. Results are presented in pg/ml for serum samples and pg/200 mg tissue for tissue samples and represent the mean of five animals + SEM. c Indicates p ⁇ 0.05 when compared to either placebo for serum samples or the difference between treated tissue and control tissue from the same animal.
  • Table 5 summarizes topical formulations made in accordance with the present invention in a percentage weight-by-weight basis.
  • Water phase preparation Edetate disodium was dissolved in the water. Methylparaben and propylparaben were dissolved in propylene glycol, and the solution was subsequently added to the water phase. Poloxamer 188 was then added to the water phase and mixed until dissolved. Phase combination: The oil phase was added to the water phase at ambient conditions.
  • TNF- ⁇ , MCP-1 and IFN- ⁇ following drug treatment as described in Examples 1-7.
  • a Female hairless CD rats were dosed topically with cream formulated Compound 2.
  • b TNF- ⁇ and MCP-1 were measured by ELISA.
  • IFN- ⁇ was measured by bioassay. Results are presented in pg/ml for serum samples and pg/200 mg tissue for tissue samples and represent the mean of five animals + SEM.
  • c Indicates p ⁇ 0.05 when compared to either placebo for serum samples or the difference between treated tissue and control tissue from the same animal.
  • a multiple dose study was done to monitor effects of a multiple dose regimen (Study 2 with results shown in Table 7). Rats were dosed two times a week for six hours for three weeks with topical cream formulation of Example 10. Placebo (Comparative Example CI) and single dosed rats were done for comparison and done simultaneously with the last dosing of the multiple dose set. Serum and tissue samples were taken at 16 and 24 hours post dose and analyzed for MCP-1.
  • a Female hairless CD rats were dosed topically with cream formulated Compound 2.
  • b MCP-1 was measured by ELISA. Results are presented in pg/ml for serum samples and pg/200 mg tissue for tissue samples and represent the mean of five animals + SEM. °lndicates p ⁇ 0.05 when compared to either placebo for serum samples or the difference between treated tissue and control tissue from the same animal.
  • a dose response study (Study 3 with results shown in Table 8) was performed by dosing with the topical cream formulations of Examples 8-11, containing various concentrations of IRM Compound 2. Serum and tissue samples were taken at 16 and 24 hours post dose and analyzed for MCP-1. The studies tested topical delivery of creams comprising IRM Compound 2 for its ability to affect a local MCP-1 induction at four concentrations.
  • Table 9 summarizes topical formulations made in accordance with the present invention on a percentage weight-by-weight basis.
  • Table 10 summarizes topical formulations made in accordance with the present invention on a percentage weight-by-weight basis.
  • the IRM compound was dissolved in isostearic acid and diisopropyl dimer dilinoleate (or caprylic/capric acid triglyceride) with heat if necessary.
  • Water phase preparation :
  • Edetate disodium was dissolved in the water. Poloxamer 188 was then added to the water phase and mixed until dissolved. Carbomer 980 was then added to the water phase and mixed until the carbomer was fully dispersed and hydrated. Methylparaben and propylparaben were dissolved in diethylene glycol monoethyl ether and the solution was subsequently added to the water phase.
  • the water phase was added to the oil phase at ambient conditions.
  • the emulsion was then mixed at high speed or homogenized.
  • sodium hydroxide solution (20%) w/w) was added and the resulting cream was mixed until smooth and uniform.
  • the pH of the cream was measured and a pH adjustment was made with additional sodium hydroxide solution, if necessary, to meet the in-process target pH of 5.
  • Table 11 summarizes topical formulations made in accordance with the present invention on a percentage weight-by-weight basis.
  • Topical creams containing the IRM compounds listed in Table 12 were prepared using the general methods described above for Examples 1 - 24. Each IRM was formulated into one or more of the model formulations shown in Tables 13 and 14. Table 15 summarizes the topical creams that were prepared. Table 12
  • Example 29 -135 The topical creams of Examples 29 -135 were tested using the test method described below. The results are shown in Table 16 below where each value is the mean of the values from the 3 rats in the treatment group.
  • the rats are acclimated to collars around the neck on two consecutive days prior to actual dosing.
  • a 50 ⁇ L dose of active cream or the appropriate placebo is applied to the right flank and gently rubbed into the skin of the rat.
  • the rats are then collared and housed individually to prevent ingestion of the drug.
  • the rats are anesthetized, and blood (3 mis) is collected by cardiac puncture. Blood is allowed to clot at room temperature. Serum is separated from the clot via centrifugation, and stored at -20°C until it is analyzed for MCP-1 concentration. Following blood collection, the rats are euthanized, and their skins removed.
  • Tissue samples (4 from each site) from both the treated site and contralateral site (untreated) are obtained using an 8 mm punch biopsy, weighed, placed in a sealed 1.8 ml cryovial, and flash frozen in liquid nitrogen. The frozen tissue sample is then suspended in 1.0 mL RPMI medium (Celox, Hopkins, MN) containing 10%) fetal bovine serum (Sigma, St. Louis, MO), 2 mM L-glutamine, penicillin streptomycin, and 2-mercaptoethanol (RPMI complete) combined with a protease inhibitor cocktail set III (Calbiochem, San Diego, CA). The tissue is homogenized using a Tissue TearorTM (Biospec Products, Bartlesville, OK) for approximately 1 minute. The tissue suspension is then centrifuged at 2000 rpm for 10 minutes under refrigeration to pellet debris, and the supernatant is collected and stored at -20°C until analyzed for MCP-1 concentration.
  • RPMI medium Celox, Hopkins, MN
  • fetal bovine serum S
  • ELISAs for rat MCP-1 are purchased from BioSource Intl. (Camarillo, CA) and performed according to manufacturer's specifications. Results are expressed in pg/ml, the values for the tissue samples are normalized per 200 mg of tissue. The sensitivity of the MCP-1 ELISA is 12 pg/ml.
  • **MCP-1 concentration is for the treated site.
  • Example 82 ***The cream of Example 82 was used in 2 separate experiments
  • Table 17 summarizes topical formulations made in accordance with the present invention on a percentage weight-by-weight basis.
  • Example 136 -140 The topical creams of Examples 136 -140 were tested using the test method described below. The results are shown in Table 18 below where each value is the mean of the values from the 3 rats in the treatment group. "Normal animals" did not receive any treatment.
  • Tissue samples (4 from each site) from both the treated site and contralateral site (untreated) are obtained using an 8 mm punch biopsy, weighed, placed in a sealed 1.8 ml cryovial, and flash frozen in liquid nitrogen. The frozen tissue sample is then suspended in 1.0 mL RPMI medium (Celox, Hopkins, MN) containing 10%> fetal bovine serum (Sigma, St. Louis, MO), 2 mM L-glutamine, penicillin/streptomycin, and 2-mercaptoethanol (RPMI complete) combined with a protease inhibitor cocktail set III (Calbiochem, San Diego, CA).
  • tissue is homogenized using a Tissue TearorTM (Biospec Products, Bartlesville, OK) for approximately 1 minute.
  • the tissue suspension is then centrifuged at 2000 rpm for 10 minutes under refrigeration to pellet debris.
  • the supernatant is collected and stored at -20°C until analyzed for cytokine concentrations.
  • ELISAs for rat MCP-1 are purchased from BioSource Intl. (Camarillo, CA) and rat TNF- ⁇ are purchased from BD Pharmingen (San Diego, CA) and performed according to manufacturer's specifications. Results are expressed in pg/ml, the values for the tissue samples are nonnalized per 200 mg of tissue. The sensitivity of the
  • MCP-1 ELISA is 12 pg/ml and the sensitivity of the TNF- ⁇ ELISA is 31 pg/ml.

Abstract

Pharmaceutical formulations comprising an immune response modifier (IRM) chosen from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo-quinolineamines, oxazolo-quinolinamines, thiazolo-pyridinamines, oxazolo-pyridinamines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid are useful for the treatment of dermal associated conditions. Novel topical formulations are provided. In one embodiment, the topical formulations are advantageous for treatment of actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts.

Description

PHARMACEUTICAL FORMULATIONS COMPRISING AN IMMUNE RESPONSE MODIFIER
Field of the Invention
The present invention is directed to pharmaceutical formulations comprising at least one immune response modifier chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines. Embodiments of the present invention are directed to topical formulations for application to the skin of a mammal. Other embodiments of the present invention are directed to methods for treating dermal diseases.
Background
Many imidazoquinoline amine, imidazopyridine amine, 6,7-fused cycloalkylimidazopyridine amine, 1,2-bridged imidazoquinoline amine, thiazoloquinoline amine, oxazoloquinoline amine, thiazolopyridine amine, oxazolopyridine amine, imidazonaphthyridine amine, imidazotetrahydronaphthyridme amine, and thiazolonaphthyridine amine compounds have demonstrated potent immunostimulating, antiviral and antitumor (including anticancer) activity, and have also been shown to be useful as vaccine adjuvants. These compounds are hereinafter collectively referred to as "IRM" (immune response modifier) compounds. One of these IRM compounds, known as imiquimod, has been commercialized in a topical formulation, Aldara™, for the treatment of anogenital warts associated with human papillomavirus.
The mechanism for the antiviral and antitumor activity of these IRM compounds is thought to be due in substantial part to enhancement of the immune response by induction of various important cytokines (e.g., interferons, interleukins, tumor necrosis factor, etc.).
Such compounds have been shown to stimulate a rapid release of certain monocyte/macrophage-derived cytokines and are also capable of stimulating B cells to secrete antibodies which play an important role in these IRM compounds' antiviral and antitumor activities. One of the predominant immunostimulating responses to these compounds is the induction of interferon (IFN)-α production, which is believed to be very important in the acute antiviral and antitumor activities seen. Moreover, up regulation of other cytokines such as, for example, tumor necrosis factor (TNF), Interleukin-1 (IL-1) and IL-6 also have potentially beneficial activities and are believed to contribute to the antiviral and antitumor properties of these compounds.
Although some of the beneficial effects of IRMs are known, the ability to provide therapeutic benefit via topical application of an IRM compound for treatment of a particular condition at a particular location may be hindered by a variety of factors. These factors include irritation of the skin to which the formulation is applied, formulation wash away, insolubility and/or degradation of the IRM compound in the formulation, physical instability of the formulation (e.g., separation of components, thickening, precipitation/agglomerization of active ingredient, and the like), poor permeation, and undesired systemic delivery of the topically applied IRM compound. Accordingly, there is a continuing need for new methods and formulations to provide the greatest therapeutic benefit from this class of compounds.
Summary of the Invention At several locations throughout the specification, guidance is provided through lists of examples. In each instance, the recited list serves only as a representative group; it is not meant that the list is exclusive.
In one aspect, the present invention is directed to a pharmaceutical formulation comprising an immune response modifier selected from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms; and a hydrophilic viscosity enhancing agent selected from cellulose ethers and carbomers. In one embodiment, the pharmaceutical formulation comprises an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms.
The formulation can further comprise one or more of a preservative system, an emulsifier, and water.
In another aspect, the present invention is directed to a method of treatment of a dermal associated condition comprising applying to skin a topical formulation comprising an immune response modifier selected from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms; and a hydrophilic viscosity enhancing agent selected from cellulose ethers and carbomers.
In one embodiment, the method of treatment of a dermal associated condition comprises applying to skin a formulation comprising an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms.
In other embodiments, the method of treatment of a dermal associated condition comprises applying to skin a formulation comprising an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms; and further comprising one or more of a preservative system, an emulsifier, and water. In one embodiment, the dermal associated condition is selected from actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts. In another aspect, the present invention is directed to a method for delivering an immune response modifier to a dermal surface, the method comprising the steps of selecting a formulation comprising a compound selected from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazoloquinoline amines, oxazolo-quinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms; and a hydrophilic viscosity enhancing agent selected from cellulose ethers and carbomers; and applying the selected formulation to the dermal surface for a time sufficient to allow the formulation to deliver the IRM to the dermal surface.
In one embodiment, the selected formulation comprises an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms.
Unless otherwise indicated, all numbers expressing quantities, ratios, and numerical properties of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about".
As used herein, "a" or "an" or "the" are used interchangeably with "at least one", to mean "one or more" of the element being modified.
Detailed Description
In one aspect, the present invention is directed to a fonnulation comprising an immune response modifier compound selected from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms, and a hydrophilic viscosity enhancing agent selected from cellulose ethers and carbomers.
These immune response modifier compounds, methods of making them, methods of using them and compositions containing them are disclosed in U.S. Patent Nos.
4,689,338 4,929,624; 4,988,815; 5,037,986 5,175,296; 5,238,944; 5,266,575; 5,268,376; 5,346,905 5,352,784; 5,367,076; 5,389,640 5,395,937; 5,446,153; 5,482,936; 5,693,811; 5,741,908 5,756,747; 5,939,090; 6,039,969 6,083,505; 6,110,929; 6,194,425; 6,245,776; 6,331,539 6,376,669; and 6,451,810; European Patent 0 394 026; US Publication 2002/0055517; and PCT Publications WO 00/47719; WO 00/76518; WO 01/74343; WO
02/46188; WO 02/ 46189; WO 02/46190; WO 02/46191; WO 02/46192; WO 02/46193; WO 02/46194; and WO 02/46749 the disclosures of which are incorporated by reference herein.
As noted above, many of the IRM compounds useful in the present invention have demonstrated significant immunomodulating activity. In certain embodiments of the present invention, the IRM compound can be chosen from imidazoquinoline amines, for example, lH-imidazo[4,5-c]quinolin-4-amines defined by one of Formulas I-V below:
Figure imgf000007_0001
I
wherein
Rπ is chosen from alkyl of one to ten carbon atoms, hydroxyalkyl of one to six carbon atoms, acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms, benzyl, (phenyl)ethyl and phenyl, said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that if said benzene ring is substituted by two of said moieties, then said moieties together contain no more than six carbon atoms;
R21 is chosen from hydrogen, alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that when the benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and each Ri is independently chosen from alkoxy of one to four carbon atoms, halogen, and alkyl of one to four carbon atoms, and n is an integer from 0 to 2, with the proviso that if n is 2, then said R\ groups together contain no more than six carbon atoms;
Figure imgf000008_0001
π
wherein R12 is chosen from straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is chosen from straight chain or branched chain alkyl containing one to four carbon atoms and cycloalkyl containing three to six carbon atoms; and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; and
R2 is chosen from hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently chosen from straight chain or branched chain alkyl containing one to four carbon atoms, straight chain or branched chain alkoxy containing one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and each R2 is independently chosen from straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R2 groups together contain no more than six carbon atoms;
Figure imgf000009_0001
m wherein R23 is chosen from hydrogen, straight chain or branched chain alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently chosen from straight chain or branched chain alkyl of one to four carbon atoms, straight chain or branched chain alkoxy of one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and each R3 is independently chosen from straight chain or branched chain alkoxy of one to four carbon atoms, halogen, and straight chain or branched chain alkyl of one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R3 groups together contain no more than six carbon atoms;
Figure imgf000010_0001
R, IN
wherein
R14 is -CHRxRy wherein Ry is hydrogen or a carbon-carbon bond, with the proviso that when Ry is hydrogen Rx is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1 -alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, or 2-, 3-, or 4-pyridyl, and with the further proviso that when Ry is a carbon-carbon bond Ry and Rx together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently chosen from hydroxy and hydroxyalkyl of one to four carbon atoms;
R24 is chosen from hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen; and is chosen from hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms;
Figure imgf000010_0002
R<
V
wherein R15 is chosen from: hydrogen; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is chosen from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is chosen from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms; benzyl; (phenyl) ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; R25 is
Figure imgf000011_0001
wherein
Rs and Rτ are independently chosen from hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen;
X is chosen from alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, hydroxyalkyl of one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, chloro, hydroxy, 1-morpholino, 1-pyrrolidino, alkylthio of one to four carbon atoms; and
R5 is chosen from hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms; and a pharmaceutically acceptable salt of any of the foregoing.
The IRM compound can also be chosen from 6,7 fused cycloalkylimidazopyridine amines defined by Formula VI below:
Figure imgf000012_0001
VI
wherein m is 1, 2, or 3;
Rι6 is chosen from hydrogen; cyclic alkyl of tliree, four, or five carbon atoms; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is chosen from cycloalkyl containing tliree to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; fluoro- or chloroalkyl containing from one to ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is chosen from cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms, with the proviso that any such alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxyalkyl, alkoxyalkyl, or acyloxyalkyl group does not have a fully carbon substituted carbon atom bonded directly to the nitrogen atom; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; and -CHRχRy wherein
Ry is hydrogen or a carbon-carbon bond, with the proviso that when Ry is hydrogen Rx is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1- alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, or 2-, 3-, or 4-pyridyl, and with the further proviso that when Ry is a carbon-carbon bond Ry and Rx together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently chosen from hydroxy and hydroxyalkyl of one to four carbon atoms,
R26 is chosen from hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, straight chain or branched chain hydroxyalkyl containing one to six carbon atoms, morpholinoalkyl, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by a moiety chosen from methyl, methoxy, and halogen; and
-C(Rs)(Rτ)(X) wherein Rs and Rτ are independently chosen from hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen; X is chosen from alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, alkylthio of one to four carbon atoms, and morpholinoalkyl wherein the alkyl moiety contains one to four carbon atoms, and
R6 is chosen from hydrogen, fiuoro, chloro, straight chain or branched chain alkyl containing one to four carbon atoms, and straight chain or branched chain fiuoro- or chloroalkyl containing one to four carbon atoms and at least one fluorine or chlorine atom; and pharmaceutically acceptable salts thereof.
In other embodiments of the present invention, the LRM compound can be chosen from imidazopyridine amines defined by Formula VII below:
Figure imgf000014_0001
wherein
Rπ is chosen from hydrogen; -CH2Rw wherein R is chosen from straight chain, branched chain, or cyclic alkyl containing one to ten carbon atoms, straight chain or branched chain alkenyl containing two to ten carbon atoms, straight chain or branched chain hydroxyalkyl containing one to six carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms, and phenylethyl; and -CH=CRzRz wherein each Rz is independently straight chain, branched chain, or cyclic alkyl of one to six carbon atoms;
R27 is chosen from hydrogen; straight chain or branched chain alkyl containing one to eight carbon atoms; straight chain or branched chain hydroxyalkyl containing one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl oand phenyl being optionally substituted on the benzene ring by a moiety chosen from methyl, methoxy, and halogen; and morpholinoalkyl wherein the alkyl moiety contains one to four carbon atoms;
R67 and R77 are independently chosen from hydrogen and alkyl of one to five carbon atoms, with the proviso that R67 and R77 taken together contain no more than six carbon atoms, and with the further proviso that when R is hydrogen then R6 is other than hydrogen and R27 is other than hydrogen or morpholinoalkyl, and with the further proviso that when R6 is hydrogen then R 7 and R27 are other than hydrogen; and pha riaceutically acceptable salts thereof. In yet another embodiment of the present invention, the IRM compound can be chosen from 1,2-bridged imidazoquinoline amines defined by Formula VIII below:
Figure imgf000015_0001
wherein
Z is chosen from: -(CH2)P- wherein p is 1 to 4;
-(CH2)a-C(RDRE)(CH2)b-, wherein a and b are integers and a+b is 0 to 3, RD is hydrogen or alkyl of one to four carbon atoms, and RE is chosen from alkyl of one to four carbon atoms, hydroxy, -ORF wherein Rp is alkyl of one to four carbon atoms, and -NRQR'G wherein RG and R'G are independently hydrogen or alkyl of one to four carbon atoms; and
-(CH2)a-(Y)-(CH2)b- wherein a and b are integers and a+b is 0 to 3, and Y is O, S, or -NRJ- wherein Rj is hydrogen or alkyl of one to four carbon atoms; and wherein q is 0 or 1 and R8 is chosen from alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, and pharmaceutically acceptable salts thereof. In a further embodiment, the IRM compound can be chosen from thiazoloquinoline amines, oxazoloquinoline amines, thiazolonaphthyridine amines, thiazolopyridine amines, and oxazolopyridine amines of Formula IX:
Figure imgf000016_0001
wherein:
R19 is chosen from oxygen, sulfur and selenium; R29 is chosen from -hydrogen;
-alkyl;
-alkyl-OH;
-haloalkyl;
-alkenyl; -alkyl-X-alkyl;
-alkyl-X-alkenyl;
-alkenyl-X-alkyl;
-alkenyl-X-alkenyl;
-alkyl-N(R59)2; -alkyl-N3;
-alkyl-O-C(O)-N(R59)2;
-heterocyclyl;
-alkyl-X-heterocyclyl;
-alkenyl-X-heterocyclyl; -aryl;
-alkyl-X-aryl; -alkenyl-X-aryl;
-heteroaryl;
-alkyl-X-heteroaryl; and
-alkenyl-X-heteroaryl; R39 and rø are each independently:
-hydrogen;
-X-alkyl;
-halo;
-haloalkyl;
-N(R59)2; or when taken together, R39 and R49 form a fused aromatic, heteroaromatic, cycloalkyl or heterocyclic ring; X is chosen from -O-, -S-, -NR59- -C(O)-, -C(O)O- -OC(O)-, and a bond; and each R59 is independently H or Cι-8alkyl; and pharmaceutically acceptable salts thereof.
In another embodiment, the IRM compound can be chosen from imidazonaphthyridine amines and imidazotetrahydronaphthyridme amines of Formulae X and XI below:
Figure imgf000017_0001
X
wherein
A is =N-CR=CR-CR=; =CR-N=CR-CR=; =CR-CR=N-CR=; or =CR-CR=CR-N=;
Rπo is chosen from:
- hydrogen; -Cι-20 alkyl or C2-20 alkenyl that is unsubstituted or substituted by one or more substituents chosen from:
-aryl;
-heteroaryl; -heterocyclyl;
-O-d.20 alkyl,
-O-(C1-2o alkyl)0-1-aryl;
-O-(Ci-2o alkyl)o-ι -heteroaryl;
-O-(Cι.2Q alkyl)o-ι-heterocyclyl; -CO-O-Cι-20 alkyl;
-S(O)o-2 -Cι.2o alkyl;
-S(O)o-2-(C1-20 alkyl)0-1-aryl;
-S(O)o-2 -(Cι-20 alkyl)o-ι -heteroaryl;
-S(O)o-2 -(C1-2o alkyl)0-1 -heterocyclyl; -N(R310)2;
-N3; oxo;
-halogen;
-NO2; -OH; and
-SH; and -Cι-20 alkyl-NR310-Q-X-R4io or -C2-20 alkenyl-NR310-Q-X-R4io wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR 10- and no is aryl; heteroaryl; heterocyclyl; or -Cι-2o alkyl or C2-2o alkenyl that is unsubstituted or substituted by one or more substituents chosen from:
-aryl;
-heteroaryl;
-heterocyclyl;
-O-Cι-20 alkyl, -O-(Ci-2o alkyl)o-i-aryl;
-O-(C1-2o alkyl)o-ι -heteroaryl;
-O-(C1-20 alkyl)0-ι -heterocyclyl; -CO-O-Ci-20 alkyl;
-S(O)o-2 -Cι.2o alkyl;
-S(O)0-2-(Ci-2o alkyl)0-ι-aryl;
-S(O)o-2 -(C1-20 alkyl)0-ι -heteroaryl; -S(O)o-2-(Ci-2o alkyl)0-ι -heterocyclyl;
-N(R310)2;
- R310-CO-O-C1.20 alkyl;
-N3; oxo; -halogen;
-NO2;
-OH; and
-SH; or R^o is
Figure imgf000019_0001
wherein Y is -N- or -CR-; R21o is chosen from: -hydrogen; -CLIO alkyl; -C2-10 alkenyl;
-aryl;
-Ci-io alkyl -O-C1-10 alkyl; -Ci-io alkyl-O-C2-10 alkenyl; and
-Ci-io alkyl or C2-10 alkenyl substituted by one or more substituents chosen from: -OH;
-halogen;
Figure imgf000019_0002
-CO-N(R310)2; -CO-Ci-io alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; each R31o is independently chosen from hydrogen and CMO alkyl; and each R is independently chosen from hydrogen, C1-10 alkyl, CMO alkoxy, halogen and trifluoromethyl, and pharmaceutically acceptable salts thereof;
Figure imgf000020_0001
XI
wherein
B is -NR-C(R)2-C(R)2-C(R)2-; -C(R)2-NR-C(R)2-C(R)2-; -C(R)2-C(R)2-NR-C(R)2- or -C(R)2-C(R)2-C(R)2-NR-; Riπ is chosen from: - hydrogen; -Ci.20 alkyl or C2-2o alkenyl that is unsubstituted or substituted by one or more substituents chosen from: -aryl;
-heteroaryl; -heterocyclyl; -O-C ι-2o alkyl;
-O-(Cι-2o alkyl)0-i-aryl;
Figure imgf000020_0002
-O-(Cι-2o alkyl)o-ι-heterocyclyl;
-CO-O-Cι.20 alkyl;
-S(O)o-2 -Cι.2o alkyl;
-S(O)o-2-(Cι-20 alkyl)0-ι-aryl; -S(O)0-2-(Ci-2o alkyl)0-i -heteroaryl;
-S(O)0-2 -(Ci.20 alkyl)0-i -heterocyclyl;
-N(R311)2;
-N3; oxo; -halogen;
-NO2;
-OH; and
-SH; and -Cι-20 alkyl-NR311-Q-X-R4iι or -C2-20 alkenyl-NR311-Q-X-R4iι wherein Q is -CO- or -SO2-; X is a bond, -O- or -NR311- and m is aryl; heteroaryl; heterocyclyl; or -Cι-2o alkyl or C2-2o alkenyl that is unsubstituted or substituted by one or more substituents chosen from:
-aryl;
-heteroaryl; -heterocyclyl;
-O-Cι.20 alkyl,
-O-(Cι-2o alkyl)o.i-aryl;
-O-(C1-2o alky^o-rheteroaryl;
-O-(Cι-2o alkyl)o-ι-heterocyclyl; -CO-O-Cι-20 alkyl;
-S(O)o-2 -Cι.2o alkyl;
-S(O)0-2-(Cι-20 alkyl)0-ι-aryl;
-S(O)o-2 -(Cι-20 alkyl)0-1 -heteroaryl;
-S(O)o-2-(Cι.2o alkyl)o.ι-lιeterocyclyl; -N(R3n)2;
-NR311-CO-O-C1.20 alkyl;
-N3; oxo;
-halogen; -NO2; -OH; and
-SH; or R4π is
Figure imgf000022_0001
wherein Y is -N- or -CR-; hosen from: -hydrogen; -Ci-io alkyl;
-C2-10 alkenyl; -aryl
-Ci-io alkyl -O- -io-alkyl; -Ci-io alkyl-O-C2-ιo alkenyl; and -Ci-io alkyl or C2-10 alkenyl substituted by one or more substituents chosen from:
-OH; -halogen; -N(R311)2; -CO-N(R311)2; -CO-Ci-io alkyl;
-N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and
-CO-heteroaryl; each R3π is independently chosen from hydrogen and C1-10 alkyl; and each R is independently chosen from hydrogen, C1-10 alkyl, C1-10 alkoxy, halogen and trifiuoromethyl, and pharmaceutically acceptable salts thereof.
In a further embodiment, the IRM compound can be chosen from imidazoquinoline amines and imidazotetrahydroquinoline amines, for example, lH-imidazo[4,5-c]quinolin- 4-amines and tetrahydro-lH-imidazo[4,5-c]quinolin-4-amines defined by Formulas XII, XIII and XIV below:
Figure imgf000023_0001
XII
wherein
R112 is -alkyl-NR312-CO-R412 or -alkenyl-NR3ι2-CO- R^ wherein u2 is aryl, heteroaryl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents chosen from: -alkyl;
-alkenyl; -alkynyl; -(alkyl)o-ι-aryl; -(alkyl)o-ι -(substituted aryl); -(alkyl)o-ι -heteroaryl;
-(alkyl)o-ι -(substituted heteroaryl); -O-alkyl; -O-(alkyl)0-1-aryl; -O-(alkyl)o-ι -(substituted aryl); -O-(alkyl)0-1-heteroaryl;
-O-(alkyl)o-ι -(substituted heteroaryl);
-CO-aryl;
-CO-(substituted aryl); -CO-heteroaryl;
-CO-(substituted heteroaryl);
-COOH;
-CO-O-alkyl; -CO-alkyl;
-S(O)0-2 -alkyl;
-S(O)0-2-(alkyl)0-ι-aryl;
-S(O)o-2 -(alkyl)0-1-(substituted aryl);
-S(O)o-2-(alkyl)o-ι-heteroaryl; -S(O)0-2-(alkyl)0-1-(substituted heteroaryl);
-P(O)(OR312)2;
-NR312-CO-O-alkyl;
-N3;
-halogen; -NO2;
-CN;
-haloalkyl;
-O-haloalkyl;
-CO-haloalkyl; -OH;
-SH; and in the case of alkyl, alkenyl, or heterocyclyl, oxo;
Figure imgf000024_0001
wherein Rs12 is an aryl, (substituted aryl), heteroaryl, (substituted heteroaryl), heterocyclyl or (substituted heterocyclyl) group; R212 is chosen from: -hydrogen; -alkyl; -alkenyl;
-aryl; -(substituted aryl); -heteroaryl;
-(substituted heteroaryl); -heterocyclyl; -(substituted heterocyclyl);
-alkyl -O-alkyl; -alkyl-O-alkenyl; and
-alkyl or alkenyl substituted by one or more substituents chosen from: -OH; -halogen;
-N(R312)2; -CO-N(R312)2; -CO-CMO alkyl; -CO-O-C1-10 alkyl; -N3;
-aryl;
-(substituted aryl); -heteroaryl;
-(substituted heteroaryl); -heterocyclyl;
-(substituted heterocyclyl); -CO-aryl; and -CO-heteroaryl; each R312 is independently chosen from hydrogen; CMO alkyl-heteroaryl; CMO alkyl-(substituted heteroaryl); C1-10 alkyl-aryl; C1-10 allcyl-(substituted aryl) and C1-10 alkyl; v is 0 to 4; and each R12 present is independently chosen from C1-10 alkyl, .io alkoxy, halogen and trifluoromethyl;
Figure imgf000026_0001
XIII wherein
Rπ3 is -alkyl-NR313- SO2 -X-R413 or -alkenyl-NR313- SO2 -X-R413 ; X is a bond or -NR513-;
R413 is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents chosen from:
-alkyl;
-alkenyl; -aryl;
-heteroaryl;
-heterocyclyl;
-substituted cycloalkyl;
-substituted aryl; -substituted heteroaryl;
-substituted heterocyclyl;
-O-alkyl;
-O-(alkyl)o-raryl;
-O-(alkyl)o-1 -substituted aryl; -O-(alkyl)0-ι -heteroaryl;
-O-(alkyl)o-ι -substituted heteroaryl;
-O-(alkyl)0-ι -heterocyclyl;
-O-(alkyl)0-1 -substituted heterocyclyl;
-COOH; -CO-O-alkyl;
-CO-alkyl;
-S(O)o-2 -alkyl;
-S(O)0-2-(alkyl)0-ι-aryl; -S(O)o-2 -(alkyl)0-1 -substituted aryl;
-S(O)o-2 -(alkyl)o-ι -heteroaryl;
-S(O)o-2 -(alkyl)o-ι-substituted heteroaryl;
-S(O)0-2-(alkyl)0-ι-heterocyclyl; -S(O)o-2-(alkyl)o-1-substituted heterocyclyl;
-(alkyl)0-1-NR313R3ι3;
-(alkyl)0-ι-NR3ι3-CO-O-alkyl;
-(alkyl)o-ι -NR3 j3-CO-alkyl;
-(alkyl)0-ι-NR313-CO-aryl; -(alkyl)0-i-NR3i3-CO-substituted aryl;
-(alkyl)0-1-NR3ι -CO-heteroaryl;
-(alky^o-rNRsπ-CO-substituted heteroaryl;
-N3;
-halogen; -haloalkyl;
-haloalkoxy;
-CO-haloalkyl;
-CO-haloalkoxy;
-NO2; -CN;
-OH;
-SH; and in the case that R«3 is alkyl, alkenyl, or heterocyclyl, oxo; chosen from:
-hydrogen; -alkyl;
-alkenyl;
-aryl;
-substituted aryl;
-heteroaryl; -substituted heteroaryl;
- alkyl-O-alkyl;
- alkyl-O- alkenyl; and - alkyl or alkenyl substituted by one or more substituents chosen from: -OH; -halogen; -N(R313)2; -CO-N(R313)2;
-CO-Ci.io alkyl; -CO-O-Ci-io alkyl; -N3; -aryl; -substituted aryl;
-heteroaryl; -substituted heteroaryl; -heterocyclyl; -substituted heterocyclyl; -CO-aryl;
-CO-(substituted aryl); -CO-heteroaryl; and -CO-(substituted heteroaryl); each R313 is independently chosen from hydrogen, C1- 0 alkyl, and when X is a bond R313 and Rn3 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring;
R513 is chosen from hydrogen, CM0 alkyl, and u3 and R513 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring; v is 0 to 4 and each Rχ3 present is independently chosen from C1-10 alkyl, C O alkoxy, halogen and trifluoromethyl;
Figure imgf000029_0001
XIV
wherein R114 is -alkyl-NR3i4-CY-NR5i4-X-R4i4 or -alkenyl-NR314-CY- NR514-X- 414 wherein
Y is =O or =S; X is a bond, -CO- or -SO2-; t is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents chosen from:
-alkyl;
-alkenyl;
-aryl;
-heteroaryl; -heterocyclyl;
-substituted aryl;
-substituted heteroaryl;
-substituted heterocyclyl;
-O-alkyl; -O-(alkyl)o-ι-aryl;
-O-(alkyl)o-ι -substituted aryl;
-O-(alkyl)o-ι-heteroaryl;
-O-(alkyl)o-ι -substituted heteroaryl;
-O-(alkyl)0-ι -heterocyclyl; -O-(alkyl)o-ι -substituted heterocyclyl;
-COOH;
-CO-O-alkyl;
-CO-alkyl; -S(O)0-2 -alkyl;
-S(O)0-2-(alkyl)0-ι-aryl;
-S(O)o-2 -(alkyl)o-ι -substituted aryl;
-S(O)o-2 -(alkyl)o-ι -heteroaryl;
-S(O)o-2 -(alkyl)o-ι -substituted heteroaryl;
-S(O)o-2-(alkyl)o-ι-heterocyclyl;
-S(O)o_2 -(alkyl)o-ι-substituted heterocyclyl;
-(alkyl)o. -NR314R314;
-(alkyl)o. -NR314-CO-O-alkyl;
-(alkyl)o. -NR314-CO-alkyl;
-(alkyl)o- -NR314-CO-aryl;
-(alkyl)o- -NR3ι4-CO-substituted aryl;
-(alkyl)o- -NR3 ι4-CO-heteroaryl;
-(alkyl)o- -NR314-CO-substituted heteroaryl;
-N3;
-halogen:
-haloalkyl;
-haloalkoxy;
-CO-haloalkoxy;
-NO2;
-CN;
-OH;
-SH; and, in the case that R4ι is alkyl, alkenyl or heterocyclyl, oxo; with the proviso that when X is a bond Ru4 can additionally be hydrogen; R2i4 is chosen from:
-hydrogen;
-alkyl;
-alkenyl;
-aryl;
-substituted aryl;
-heteroaryl;
-substituted heteroaryl; - alkyl -O-alkyl; -alkyl-O- alkenyl; and
- alkyl or alkenyl substituted by one or more substituents chosen from:
-OH; -halogen;
-N(R314)2; -CO-N(R314)2; -CO-C1-10 alkyl; -CO-O-CMO alkyl; -N3;
-aryl;
-substituted aryl; -heteroaryl; -substituted heteroaryl; -heterocyclyl;
-substituted heterocyclyl; -CO-aryl;
-CO-(substituted aryl); -CO-heteroaryl; and -CO-(substituted heteroaryl); each R314 is independently chosen from hydrogen and C O alkyl; Rs1 is chosen from hydrogen, Ci-io alkyl, and R414 and R514 can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring; v is 0 to 4 and each R1 present is independently chosen from Cno alkyl, C1-10 alkoxy, halogen and trifluoromethyl, and pharmaceutically acceptable salts thereof.
In yet another embodiment, the IRM compound can be chosen from imidazoquinoline amines and imidazotetrahydroquinoline amines, for example, \H- imidazo[4,5-c]quinolin-4-amines and tetrahydro- lH-imidazo[4,5-c]quinolin-4-amines defined by Formulas XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, and XXVI below
Figure imgf000032_0001
XV
wherein: X is -CHR5ι5-, -CHR515-alkyl-, or -CHR515-alkenyl-;
Rn5 is chosen from:
-R415-CR315-Z-R615 — alkyl;
-R ι5-CR3ι5-Z-R615— alkenyl; -R415-CR3ι5-Z-R615— aryl;
-R415-CR315-Z-R6 \ 5 — hetero aryl;
Figure imgf000032_0002
-R4i5-NR715 -CR315-R615— alkyl; -R415-NR715 -CR315- 615— alkenyl;
-R4ι5-NR715-CR3i5-R6i5-aι-yl;
-R^s-NR^s-CR^-R^s-heteroaryl;
-R4ι5-NR7ι5-CR3ι5-R615-heterocyclyl; and
-R4i5-NR ι5 — CR315-R8ι5; Z is -NR515-, -O-, or -S-;
R2i5 is chosen from:
-hydrogen;
-alkyl;
-alkenyl; -aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl-Y- alkenyl; -alkyl- Y-aryl; and - alkyl or alkenyl substituted by one or more substituents selected from the group consisting of: -OH; -halogen; -N(R5ι5)2;
-CO-N(R515)2; -CO-Ci-io alkyl; -CO-O-CMO alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; R315 is =O or =S; nδ is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each Rδts is independently H or Ci-io alkyl;
R6!5 is a bond, alkyl, or alkenyl, which may be interrupted by one or more -O- groups;
R ιs is H, CMO alkyl, arylalkyl, or R415 and R715 can join together to form a 5 to 7 membered heterocylcic ring;
Rsi5 is H, Ci-io alkyl, or R 15 and R8ι5 can join together to form a 5 to 7 membered heterocyclic ring; Y is -O- or -S(O)0-2-; v is 0 to 4; and each R15 present is independently chosen from CMO alkyl, .io alkoxy, hydroxy, halogen and trifluoromethyl;
Figure imgf000034_0001
XVI
wherein: X is -CHR516-, -CHR516-alkyl-, or -CHR516-alkenyl-; Rue is chosen from:
-R4i6-CR3ι6-Z-R6ι6— alkyl;
-R416-CR316-Z-R6I6— alkenyl;
-R416-CR3ι6-Z-R6ι6— aryl;
-R416-CR3i6-Z-R616— heteroaryl; -R416-CR316-Z-R616 — heterocyclyl;
-R416— CR3i6— Z— H;
-R416-NR7ι6 -CR316-R6I6— alkyl;
-R4i6-NR716 -CR3i6-Rsie— alkenyl;
-R416-NR7ι6-CR316-R6ι6-aryl; -R4i6-NR716-CR3i6-R6i6-heteroaryl;
-R416-NR716-CR 16-Re 6-heterocyclyl; and
-R4i6-NR7ι6 -CR316-R8ι6; Z is -NR516-, -O- or -S-; R216 is chosen from: -hydrogen;
-alkyl;
-alkenyl;
-aryl;
-heteroaryl; -heterocyclyl;
-alkyl-Y-alkyl;
-alkyl- Y- alkenyl;
-alkyl- Y-aryl; and - alkyl or alkenyl substituted by one or more substituents chosen from:
-OH; -halogen; -N(R516)2;
-CO-N(R5ι6)2; -CO-Ci-io alkyl; -CO-O-Ci.io alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; R316 is =O or =S;
R416 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R5!6 is independently H or C O alkyl;
R616 is a bond, alkyl, or alkenyl, which may be interrupted by one or more -O- groups;
R 16 is H, CI-IO alkyl, arylalkyl, or R4K5 and R 16 can join together to form a 5 to 7 membered hetercyclic ring;
Rs is H or C O alkyl; or R716 and R816 can join together to form a 5 to 7 membered heterocyclic ring; Y is -O- or -S(O)0-2-; v is 0 to 4; and each R16 present is independently chosen from .10 alkyl, CMO alkoxy, hydroxy, halogen, and trifluoromethyl;
Figure imgf000036_0001
wherein: X is -CHR317-, -CHR317-alkyl-, or -CHR317-alkenyl-; R is chosen from:
-alkenyl; -aryl; and -R4i7-aryl; R217 is chosen from: -hydrogen;
-alkyl; -alkenyl; -aryl;
-heteroaryl; -heterocyclyl;
-alkyl-Y-alkyl; -alkyl- Y- alkenyl; -alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents chosen from:
-OH; -halogen; -N(R317)2; -CO-N(R317)2; -CO-Ci-io alkyl;
-CO-O-CMO alkyl;
-N3;
-aryl;
-heteroaryl; -heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; Rt17 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R3ι is independently H or C1-10 alkyl; each Y is independently -O- or -S(O)o-2-; v is 0 to 4; and each R1 present is independently chosen from CMO alkyl, C O alkoxy, hydroxy, halogen and trifluoromethyl;
Figure imgf000037_0001
XVIII
wherein: X is -CHR318-, -CHR318-alkyl-, or -CHR318-alkenyl-;
Rπs is chosen from:
-aryl;
-alkenyl; and
Figure imgf000037_0002
R2i8 is chosen from:
-hydrogen;
-alkyl;
-alkenyl;
-aryl; -heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl- Y-aryl;
- alkyl- Y- alkenyl; and - alkyl or alkenyl substituted by one or more substituents chosen from:
-OH; -halogen; -N(R3ι8)2;
-CO-N(R318)2; -CO-Ci-io alkyl; -CO-O-CMO alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl; R418 is alkyl or alkenyl, which may be interrupted by one or more
-O- groups; each R318 is independently H or CMO alkyl; each Y is independently -O- or -S(O)o-2-; v is 0 to 4; and each Ri8 present is independently chosen from CMO alkyl, C O alkoxy, hydroxy, halogen and trifluoromethyl;
Figure imgf000038_0001
wherein: X is -CHR319-, -CHR3ι -alkyl-, or -CHR319-alkenyl-;
Ri19 is chosen from: -heteroaryl; -heterocyclyl; -R419- heteroaryl; and -R41 -heterocyclyl; R219 is chosen from: -hydrogen; -alkyl;
-alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -alkyl-Y-alkyl;
-alkyl- Y- alkenyl; -alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents chosen from: -OH;
-halogen; -N(R319)2; -CO-N(R319)2; -CO-Ci.io alkyl; -CO-O-CMO alkyl;
-N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and
-CO-heteroaryl; t!9 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each Rj19 is independently H or CMO alkyl; each Y is independently -O- or -S(O)o-2-; v is 0 to 4; and each R19 present is independently chosen from C1-10 alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl;
Figure imgf000040_0001
wherein: X is -CHR320-, -CHR32o-alkyl-, or -CHR32o-alkenyl-;
Ri2o is chosen from: -heteroaryl; -heterocyclyl;
-R420- heteroaryl; and -R42o-heterocyclyl; R22o is chosen from: -hydrogen; -alkyl;
-alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -alkyl- Y-alkyl;
-alkyl- Y- alkenyl; -alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents chosen from: -OH;
-halogen;
Figure imgf000040_0002
-CO-N(R32o)2; -CO-CMO alkyl; -CO-O-CMO alkyl;
-N3;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; R420 is alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R320 is independently H or CMO alkyl; each Y is independently -O- or -S(O)o-2S v is 0 to 4; and each R20 present is independently chosen from CMO alkyl, CMO alkoxy, hydroxy, halogen and rrifluoromethyl;
Figure imgf000041_0001
XXI
wherein: X is -CHR521-, -CHR52ι-alkyl-, or -CHR521-alkenyl-;
R12ι is chosen from:
-R4: — NR321— SO2— R<521— alkyl; -R4: — NR32ι— SO2— 621— alkenyl; -Rt: -NR321-SO2-R62i-aryl; -R4: -NR321-SO2-R621-heteroaryl; -R4 -NR321-SO2-R621-heterocyclyl; -R4: — NR321— SO2— R72U -R4: -NR32i-SO2-NR521-R62ι-alkyl; -R4: -NR321-SO2-NR52i-R62i-alkenyl; -R4: -NR321-SO2-NR52i-R62i-aryl; -R42i-NR32i-SO2-NR52i-R62i-heteroaryl; -R 21 -NR32i-SO2-NR521-R62ι -heterocyclyl; and
Figure imgf000042_0001
R22i is chosen from: -hydrogen;
-alkyl; -alkenyl; -aryl;
-heteroaryl; -heterocyclyl;
-alkyl-Y-alkyl; -alkyl- Y- alkenyl; -alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents chosen from:
-OH; -halogen; -N(R521) ; -CO-N(R521)2; -CO-C1-10 alkyl;
-CO-O-Cι-10 alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl;
-CO-aryl; and -CO-heteroaryl; Y is -O- or -S(O)o-2-; R321 is H, C1-10 alkyl, or arylalkyl; each R421 is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups, or R321 and R421 can join together to form a 5 to 7 membered heterocyclic ring; each Rs2i is independently H, CMO alkyl, or C2-10 alkenyl;
Re2i is a bond, alkyl, or alkenyl, which may be interrupted by one or more -
O- groups;
R72ι is CMO alkyl, or R32ι and R 21 can join together to fonn a 5 to 7 membered heterocyclic ring; v is 0 to 4; and each R21 present is independently chosen from C O alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl;
Figure imgf000043_0001
XXII
wherein: X is -CHR522-, -CHR522-alkyl-, or -CHR522-alkenyl-;
R122 is chosen from: -R422—NR322—SO2—R622— alkyl;
-R422 — NR322 — SO2 — Rg22 — alkenyl; -R422-NR322-SO2-R622-aryl; -R422-NR322-SO2-R622-heteroaryl; -R422-NR322-SO2-R<522-heterocycryl; -R422— NR322— SO2— R722;
-R422-NR322-SO2-NR522-R622-alkyl; -R422-NR322-SO2-NR522-R622-alkenyl; -R 22-NR322-SO2-NR522-R622-aryl; -R422-NR322-SO2-NR522-R622-heteroaryl; -R422-NR322-Sθ2-NR522-R622-heterocyclyl; and
Figure imgf000043_0002
R222 is chosen from: -hydrogen; -alkyl; -alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -alkyl-Y-alkyl;
-alkyl- Y- alkenyl; -alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents chosen from: -OH;
-halogen; -N(R522)2; -CO-N(R522)2; -CO-CMO alkyl; -CO-O-CMO alkyl;
-N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and
-CO-heteroaryl; Y is -O- or -S(O)o-2-; R322 is H, C O alkyl, or arylalkyl; each R_j22 is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups, or R322 and R 22 can join together to fonn a 5 to 7 membered heterocyclic ring; each R522 is independently H, CMO alkyl, or C2-10 alkenyl; R622 is a bond, alkyl, or alkenyl, which may be interrupted by one or more - O- groups; R722 is CMO alkyl, or R322 and R72 can join together to form a 5 to 7 membered heterocyclic ring; v is 0 to 4; and each R22 present is independently chosen from CMO alkyl, CMO alkoxy, hydroxy, halogen, and trifluoromethyl;
Figure imgf000045_0001
XXIII
wherein: X is -CHR323-, -CHR323-alkyl-, or -CHR323-alkenyl-;
Z is -S-, -SO-, or-SO2-; R123 is chosen from: -alkyl;
-aryl;
-heteroaryl; -heterocyclyl; -alkenyl; -R423-aryl;
-R 23- heteroaryl; -R 23-heterocyclyl; R223 is chosen from: -hydrogen; -alkyl;
-alkenyl; -aryl;
-heteroaryl; -heterocyclyl; -alkyl- Y-alkyl;
- alkyl- Y- alkenyl; -alkyl- Y-aryl; and
- alkyl or alkenyl substituted by one or more substituents chosen from: -OH;
-halogen;
Figure imgf000046_0001
-CO-CMO alkyl;
-CO-O-CMO alkyl;
-N3;
-aryl;
-heteroaryl; -heterocyclyl;
-CO-aryl; and
-CO-heteroaryl; each Rj23 is independently H or CMO alkyl; each j23 is independently alkyl or alkenyl; each Y is independently -O- or -S(O)o-2-; v is 0 to 4; and each R23 present is independently chosen from CMO alkyl, CMO alkoxy, hydroxy, halogen and trifluoromethyl;
Figure imgf000046_0002
XXIV
wherein: X is -CHR324-, -CHR324-alkyl-, or -CHR324-alkenyl-;
Z is -S-, -SO-, or -SO2-; R124 is chosen from:
-alkyl; -aryl;
-heteroaryl; -heterocyclyl; -alkenyl;
-R424-aryl;
-R42 - heteroaryl; and
-R424-heterocyclyl; R224 is chosen from:
-hydrogen;
-alkyl;
-alkenyl;
-aryl; -heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
- alkyl- Y- alkenyl;
-alkyl- Y-aryl; and - alkyl or alkenyl substituted by one or more substituent chosen from:
-OH; -halogen;
-N(R324)2; -CO-N(R324)2;
-CO-CMO alkyl; -CO-O-CMO alkyl; -N3; -aryl; -heteroaryl;
-heterocyclyl; -CO-aryl; and -CO-heteroaryl; each R324 is independently H or CMO alkyl; each R424 is independently alkyl or alkenyl; each Y is independently -O- or -S(O)0-2-; v is 0 to 4; and each R24 present is independently chosen from CMO alkyl, C O alkoxy, hydroxy, halogen and trifluoromethyl;
Figure imgf000048_0001
wherein: X is -CHR 25-, -CHR525-alkyl-, or -CHR525-alkenyl-;
R125 is chosen from:
-R425-NR825-CR325— NR525-Z-R625-alkyl; -R425-NR825-CR325— NR525-Z-R625-alkenyl;
-R425-NR825-CR32S— NR525-Z-R625-aryl;
-R425-NR825-CR325— NR525-Z-R625-heteroaryl;
-R425-NR825-CR325— NR525-Z-R625-heterocyclyl;
-R425-NR825 — CR32 — NR525R725 ; -R425-NR825-CR325— NR925-Z— R625-alkyl;
-R425-NR825-CR325— NR925-Z— R625-alkenyl;
-R425-NR825-C 325— NR925-Z— R625-aryl;
-R 25-NRs25-CR325— NR925-Z — R625-heteroaryl; and
-R425-NR825-CR325— NR925-Z— R625-heterocyclyl; R225 is chosen from:
-hydrogen;
-alkyl;
-alkenyl;
-aryl; -heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl- Y- alkenyl;
-alkyl- Y-aryl; and - alkyl or alkenyl substituted by one or more substituents chosen from:
-OH; -halogen; -N(R525)2;
-CO-N(R525)2; -CO-Ci-io alkyl; -CO-O-CMO alkyl; -N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl;
Figure imgf000049_0001
each Rj2s is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups; each R525 is independently H or C O alkyl;
Rfi25 is a bond, alkyl, or alkenyl, which may be interrupted by one or more -O- groups;
R 25 is H, CMO alkyl which may be interrupted by a hetero atom, or R725 can join with R525 to form a 5 to 7 membered heterocyclic ring; Rs25 is H, CMO alkyl, arylalkyl, or R425 and R825 can join together to form a 5 to 7 membered heterocyclic ring; R925 is CMO alkyl which can join together with R825 to form a 5 to 7 membered heterocyclic ring; each Y is independently -O- or -S(O)o-2-; Z is a bond, -CO- or -SO2-; v is 0 to 4; and each R25 present is independently chosen from CMO alkyl, C O alkoxy, hydroxy, halogen and triffuoromethyl;
Figure imgf000050_0001
XXVI
wherein: X is -CHR526-, -CHR526-alkyl-, or -CHR526-alkenyl-; R126 is chosen from:
-R426-NR826-CR326--NR526-Z-R626-alkyl;
-R426-NR826-CR326— NR526-Z-R626-alkenyl;
-R426-NR826-CR326— NR526-Z-R626-aryl;
-R426-NR826-CR326— NR526-Z-R626-heteroaryl; -R426-NR826-CR326— NR526-Z-R626-heterocyclyl;
-R426— NR826— CR326— NR526R726;
-R426-NR826-CR326— NR926-Z— R626-alkyl;
-R426-NR826-CR326--NR926-Z— R626-alkenyl;
-R426-NR826-CR326— NR926-Z— R626-aryl; -R426-NR826-CR326— NR926-Z— R626-heteroaryl; and
-R426-NR826-CR326— NR926-Z— R626-heterocyclyl; R226 is chosen from:
-hydrogen;
-alkyl; -alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl;
-alkyl-Y-alkyl; -alkyl- Y- alkenyl;
-alkyl- Y-aryl; and
■ alkyl or alkenyl substituted by one or more substituents chosen from:
-OH; -halogen; -N(R526)2; -CO-N(R526)2;
-CO-CMO alkyl; <v -CO-O-CMO alkyl;
-N3; -aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and
-CO-heteroaryl; each R326 is =O or =S; each R426 is independently alkyl or alkenyl, which may be interrupted by one or more -O- groups; each Rs26 is independently H or CMO alkyl;
R626 is a bond, alkyl, or alkenyl, which may be interrupted by one or more -O- groups;
R726 is H, C O alkyl which may be interrupted by a hetero atom, or R726 can join with R526 to form a 5 to 7 membered heterocyclic ring; Rg26 is H, C O alkyl, arylalkyl, or R426 and R826 can join together to form a
5 to 7 membered heterocyclic ring;
R926 is CMO alkyl which can join together with R826 to fonn a 5 to 7 membered heterocyclic ring; each Y is independently -O- or -S(O)o-2-; Z is a bond, -CO- or -SO2-; v is 0 to 4; and each R26 present is independently chosen from CMO alkyl, CMO alkoxy, hydroxy, halogen, and trifluoromethyl; and pharmaceutically acceptable salts of any of the foregoing. In another embodiment, the IRM compound can be chosen from lH-imidazo[4,5- c]pyridin-4-amines compounds defined by Formula XXVII
Figure imgf000052_0001
XXVII
wherein X is alkylene or alkenylene; Y is -CO- -CS-, or -SO2-;
Z is a bond, -O-, -S-, or -NR52 -;
R127 is aryl, heteroaryl, heterocyclyl, CMO alkyl or C2-2o alkenyl, each of which may be unsubstituted or substituted by one or more substituents independently chosen from: -alkyl;
-alkenyl;
-aryl;
-heteroaryl;
-heterocyclyl; -substituted cycloalkyl;
-O-alkyl;
-O-(alkyl)o-i-aryl;
-O-(alkyl)o-ι-heteroaryl;
-O-(alkyl)0-ι-heterocyclyl; -COOH;
-CO-O-alkyl;
-CO-alkyl;
-S(O)0-2 -alkyl;
-S(O)o-2-(alkyl)o-ι-aryl; -S(O)o-2 -(alkyl)0-i -heteroaryl;
-S(O)o-2-(alkyl)o-ι-heterocyclyl;
-(alkyl)0-ι-N(R527)2;
-(alkyl)0-1-NR527-CO-O-alkyl; -(alkyl)0-i-NR527-CO-alkyl; -(alkyl)0-i-NR527-CO-aryl; -(alkyl)o-ι -NR527-CO-heteroaryl; -N3; -halogen;
-haloalkyl; -haloalkoxy; -CO-haloalkyl; -CO-haloalkoxy; -NO2;
-CN; -OH;
-SH; and in the case of alkyl, alkenyl, and heterocyclyl, oxo; chosen from: -hydrogen;
-alkyl; -alkenyl; -alkyl-O-alkyl; -alkyl-S-alkyl; -alkyl-O-aryl;
-alkyl-S^aryl: -alkyl-O- alkenyl; -alkyl-S- alkenyl; and
-alkyl or alkenyl substituted by one or more substituents chosen from:
-OH; -halogen; -N(R527)2;
Figure imgf000053_0001
-CS-N(R527)2;
Figure imgf000053_0002
-NR527-CO-CMO alkyl; -NR527-CS-CMO alkyl; -NR527-SO2-C1.10 alkyl; -CO-CMO alkyl; -CO-O-CMO alkyl; -N3;
-aryl;
-heteroaryl; -heterocyclyl; -CO-aryl; and -CO-heteroaryl;
R327 and 427 are independently chosen from hydrogen, alkyl, alkenyl, halogen, alkoxy, amino, alkylamino, dialkylamino and alkylthio; each R527 is independently H or CMoalkyl; and pharmaceutically acceptable salts thereof. As used herein, the terms "alkyl", "alkenyl" and the prefix "alk-" are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms. Preferred groups have a total of up to 10 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopropylmefhyl, cyclopentyl, cyclohexyl and adamantyl.
The term "haloalkyl" is inclusive of groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of groups that include the prefix "halo-". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.
The term "aryl" as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl. The term "heteroaryl" includes aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N). Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, and so on.
"Heterocyclyl" includes non-aromatic rings or ring systems that contain at least one ring hetero atom (e.g., O, S, N) and includes all of the fully saturated and partially unsaturated derivatives of the above mentioned heteroaryl groups. Exemplary heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, fhiazolidinyl, imidazolidinyl, isothiazolidinyl, and the like. In some embodiments, the topical formulations of the present invention are prepared using the free base form of the IRM compound. The amount of an IRM compound that will be therapeutically effective in a specific situation will depend on such things as the activity of the particular compound, the dosing regimen, the application site, the particular formulation and the condition being treated. As such, it is generally not practical to identify specific administration amounts herein; however, those skilled in the art will be able to determine appropriate therapeutically effective amounts based on the guidance provided herein, information available in the art pertaining to these compounds, and routine testing. The term "a therapeutically effective amount" means an amount of the compound sufficient to induce a therapeutic effect, such as cytokine induction, inhibition of TH2 immune response, antiviral or antitumor activity, reduction or elimination of postsurgical scarring, or reduction or resolution of actinic keratosis or pre- actinic keratosis lesions.
In general, the amount of the IRM compound present in a topical formulation of the invention will be an amount effective to treat a targeted condition, to prevent recurrence of the condition, or to promote immunity against the condition. The amount or concentration of the IRM compound can range from 0.001%) to 10% by weight based on the total formulation weight, such as, for example, from 0.03%> to 5.0%> by weight, or from
0.1 to 1.0%) by weight. In certain embodiments, the amount of the IRM compound is at least 0.003%o by weight, such as, for example, at least 0.005%, at least 0.01%o, at least 0.03%, at least 0.10%>, at least 0.30%> and at least 1.0%. In other embodiments, the amount of the IRM compound is at most 5.0%> by weight, such as, for example, at most 3.0%, and at most 1.0%.
The topical formulations of the invention additionally comprise a fatty acid. As used herein, the term "fatty acid" means a carboxylic acid, either saturated or unsaturated, comprising 6 to 28 carbon atoms, such as, for example, from 10 to 22 carbon atoms. Non-limiting examples of such fatty acids include isostearic acid, oleic acid, and linear- or- branched chained carboxylic acids of 6 to 18 carbon atoms. The fatty acid may be present in the formulation in an amount sufficient to solubilize the IRM compound. In one embodiment, the amount of the fatty acid can range from 0.05 %> to 40 % by weight based on the total weight of the formulation, such as, for example, from 1% to 30%, from 3%» to 15%o and from 5% to 10%. In certain embodiments, the amount of the fatty acid is at least 3.0%o by weight, such as, for example, at least 5.0%, at least 10.0%>, and at least 25%. The fatty acid component of the formulation can comprise one or more fatty acids. The topical formulations of the invention additionally comprise at least one hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms. By "hydrophobic" is meant that the component is essentially insoluble in water, i.e. immiscible with water and unable to form a micelle in water, and does not contain polyoxyethylene or acid salt groups. Preferably the hydrophobic, aprotic component has a hydrophilic lipophilic balance (HLB) of less than 2.
The HLB of a component maybe determined as described, for example, in Attwood, D., Florence, A. T. Surfactant Systems: Their Chemistry, Pharmacy, and Biology. New York: Chapman & Hall, 471-473, 1983. By "aprotic" is meant that the component cannot donate a proton to the IRM and does not contain groups such as carboxyl, hydroxy, primary and secondary amino, primary and secondary amido, or quaternary ammonium groups.
Preferably this component has a pKa of at least 14.2 and does not substantially solubilize or form a complex such as an acid-base pair or complex or a hydrogen bond complex with the IRM compound. By "not substantially" is meant that the ratio of the IRM compound's solubility in the hydrophilic, aprotic component to that in isostearic acid is less than 1 :40. Formulations intended for dermal or topical use desirably have a certain minimum amount of an oil phase to provide qualities such as spreadability, feel on the skin, texture, and so on. However, if all the components of the oil phase solubilize the IRM, then the degree of saturation of the IRM in the formulation will decrease, making it more difficult to deliver the IRM from the formulation to the skin. Addition of the hydrophobic, aprotic component can increase the oil phase volume of the topical formulation to provide desirable qualitites such as spreadability and feel, while at the same time not appreciably altering the degree of saturation or thermodynamic activity of the IRM. For example, the amount of fatty acid, which solubilizes the IRM, can be reduced to increase the degree of IRM saturation while maintaining a sufficient oil phase volume by virtue of the addition of the hydrophobic, aprotic component, which does not offset the increased IRM saturation. Thus, the topical formulation of the present invention can facilitate both physical property and drug delivery requirements. Degree of saturation and thermodynamic activity of the
IRM in these formulations is equal to the IRM concentration in the oil phase divided by the saturation concentration of the IRM in the oil phase. When the topical formulations of the present invention contain saturated IRM the thermodynamic activity or degree of saturation is unity, and when partially saturated the thermodynamic activity or degree of saturation is less than unity.
The amount of the hydrophobic, aprotic component present in a formulation of the invention can range from 1% to 30% by weight based on the total formulation weight, for example, from 3 % to 15%> by weight, and from 5 to 10%> by weight, hi certain embodiments, the amount of the hydrophobic, aprotic component is at least 3.0%> by weight, for example, at least 5.0%>, and at least 10.0%>. The weight ratio of the hydrophobic, aprotic component to the fatty acid can be 0.025:1 to 600:1, for example, 0.5:1 to 50:1, and 2:1 to 30:1. The combined amount (weight percent of the total topical formulation weight) of the hydrophobic, aprotic component and the fatty acid can be 2% to 50% by weight, for example 2% to 30%, 5% to 30%, 5% to 20%, and 10% to 20%. Examples of useful hydrophobic, aprotic components include but are not limited to fatty acid esters, for example, isopropyl mysristate, isopropyl palmitate, diisopropyl dimer dilinoleate; triglycerides, for example, caprylic/capric triglyceride; cetyl esters wax; hydrocarbons of 8 or more carbon atoms, for example, light mineral oil, white petrolatum; and waxes, for example, beeswax. In some embodiments, the hydrophobic, aprotic component is chosen from one or more of isopropyl mysristate, isopropyl palmitate, caprylic/capric triglyceride, and diisopropyl dimer dilinoleate.
The formulations of the present invention can also comprise a hydrophilic viscosity enhancing agent. Examples of suitable hydrophilic viscosity enhancing agents include cellulose ethers such as hydroxypropylmethylcellulose, hydroxyefhylcelfulose, hydroxypropylcellulose, and carboxymethylcellulose; polysaccharide gums such as xanthan gum; and homopolymers and copolymers of acrylic acid crosslinked with allyl sucrose or allyl pentaerythriol such as those polymers designated as carbomers in the United States Pharmacopoeia. Suitable carbomers include, for example, those available as Carbopol™ 934P, Carbopol 97 IP, Carbopol 940, Carbopol 974P, Carbopol 980, and Pemulen™ TR-1 (USP/NF Monograph; Carbomer 1342), all available from Noveon, Cleveland, Ohio. In one embodiment of the present invention, the viscosity enhancing agent is chosen from Carbopol 974P and 980. When included, the viscosity enhancing agent is generally present in an amount ranging from 0.1 %> to 10%> by weight of total formulation weight, such as, for example, from 0.5 %> to 5%> by weight, from 0.5%> to 1.5% by weight, and from 0.7%) to 3%> by weight. In certain embodiments, the amount of the viscosity enhancing agent is at least 0.5%o by weight, for example, at least 0.6% by weight, at least 0.7%> by weight, at least 0.9%> by weight, and at least 1.0% by weight.
The formulations of the invention can additionally comprise an emulsifier. Suitable emulsifiers include non-ionic surfactants such as, for example, polysorbate 60, sorbitan monostearate, polyglyceryl-4 oleate, polyoxyethylene(4) lauryl ether, etc. In certain embodiments, the emulsifier is chosen from poloxamers (e.g., Pluronic™ F68, also known as Poloxamer 188, a poly(ethylene glycol)-block-poly(propylene glycol)-block- poly(ethylene glycol), available from BASF, Ludwigshafen, Germany) and sorbitan trioleate (e.g., Span 85 available from Uniqema, New Castle, DE). If included, the emulsifier is generally present in an amount of 0.1%o to 10%o by weight of total formulation weight, for example, from 0.5%> to 5%> by weight, and from 0.75%) to 3.5%> by weight. In certain embodiments, the amount of the emulsifier is at least 1.0% by weight, for example, at least 2.5%, at least 3.5%, and at least 5.0%>.
In certain embodiments of the present invention, the formulation can also include at least one chelating agent. The chelating agent functions to chelate metal ions that may be present in the formulation. Suitable chelating agents include salts of ethylenediaminetetraacetate (EDTA), such as the disodium salt. If included, the chelating agent is generally present in an amount ranging from 0.001 % to 0.1% by weight, and preferably from 0.01% to 0.05%) by weight. In certain embodiments, the amount of the chelating agent is at least 0.005%> by weight, such as, for example, at least 0.01%, and at least 0.05%. The formulation can also include a preservative system. The preservative system is generally comprised of at least one preservative compound chosen from methylparaben, ethylparaben, propylparaben, phenoxyethanol, iodopropynyl butylcarbamate, sorbic acid, a fatty acid monoester of glycerin such as glycerol monolaurate, and a fatty acid monoester of propylene glycol such as propylene glycol monocaprylate. The preservative system may also include a preservative enhancing solubilizer which enhances the solubility of the preservative in the aqueous phase, examples of which include diethylene glycol monoethyl ether and propylene glycol. In one embodiment, the preservative system can be comprised of methylparaben, propylparaben, and propylene glycol. In another embodiment, the preservative system can be comprised of methylparaben, ethylparaben, and diethylene glycol monoethyl ether. In one embodiment, the preservative system can be comprised of phenoxyethanol, methylparaben or methyl- and ethylparaben, and diethylene glycol monoethyl ether. In another embodiment, the preservative system can be comprised of iodopropynyl butylcarbamate. In another embodiment, the preservative system can be comprised of iodopropynyl butylcarbamate, diethylene glycol monoethyl ether, and poly( ethylene glycol)(4) monolaurate. In another embodiment, the preservative system can be comprised of iodopropynyl butylcarbamate, one or more of methylparaben, ethylparaben, propylparaben, or phenoxyethanol, and diethylene glycol monoethyl ether.
In the above embodiments, the methylparaben, ethylparaben, and propylparaben can each be present in the formulations in an amount ranging from 0.01% to 0.5% by weight of the formulation weight, for example, from 0.05 %> to 0.25%> by weight, and from 0.1%o to 0.2% by weight. The iodopropynyl butylcarbamate can be present in the formulations in an amount ranging from 0.01% to 0.1%. The phenoxyethanol can be present in the formulations in an amount ranging from 0.1% to 1%>. The propylene glycol and diethylene glycol monoethyl ether can each be present in the formulations in an amount ranging from 1% to 30%o by weight of the formulation weight, such as, for example, from 5 % to 25%o by weight, and from 10%> to 15%> by weight. The preservative system can be present in the formulations in an amount ranging from 0.01%> to 30%> by weight of the formulation weight, for example, from 0.05% to 30%), from 0.1%> to 25%o by weight, and from 0.2%o to 15%) by weight. In a further embodiment, the methylparaben, ethylparaben, propylparaben, iodopropynyl butylcarbamate, and phenoxyethanol can be solubilized in propylene glycol, poly(ethylene glycol)(4) monolaurate, or diethylene glycol monoethyl ether prior to addition to the formulation. The preservative system can be selected such that it meets the criteria for antimicrobial effectiveness set forth in the United States Pharmacopeia <51>. The formulations of the present invention may additionally comprise at least one pH adjuster. Suitable pH adjusters include organic bases and inorganic bases such as, for example, KOH, NaOH. The pH of the topical formulations of the present invention generally ranges from 3.5 to 7.0. In one embodiment, the pH of the topical formulations of the present invention can range from 4.0 to 6.0, preferably 5.0. In another embodiment of the invention, the pH of the topical formulations of the present invention can range from 5.5 to 6.5, preferably 6.0.
Any of the foregoing formulations can be in the form of an oil-in- water emulsion such as a cream or a lotion. Such an emulsion can comprise an oil phase comprising the IRM compounds, a fatty acid in an amount sufficient to solubilize the IRM compounds, a hydrophobic, aprotic component; and an aqueous phase comprising a hydrophilic viscosity enhancing agent, for example, a carbomer. In certain embodiments, the amount or concentration of the IRM in the oil phase can be at least 0.01%>, for example, at least 0.02%), at least 0.1 %>, and at least 1% with respect to oil phase weight. In other embodiments, the amount or concentration of the IRM in the oil phase can be at most
20%), for example, at most 10%, and at most 5% with respect to oil phase weight. The emulsion can be preserved so that when challenged by an antimicrobial effectiveness test, it meets regulatory requirements for topical creams packaged in multiple-use containers. Any of the foregoing formulations according to the present invention can be applied to the dermal surfaces of a mammal. Depending on the IRM compound concentration, formulation composition, and dermal surface, the therapeutic effect of the IRM compound may extend only to the superficial layers of the dermal surface or to tissues below the dennal surface. Thus, another aspect of the present invention is directed to a method for the treatment of a dermal associated condition comprising applying to skin one of the foregoing formulations. As used herein, a "dermal associated condition" means an inflammatory, infectious, neoplastic or other condition that involves a dermal surface or that is in sufficient proximity to a dermal surface to be affected by a therapeutic agent topically applied to the dermal surface. Examples of a dermal associated condition include warts, atopic dermatitis, basal cell carcinoma, postsurgical scars, and actinic keratosis.
In one embodiment, the formulations can be applied to the surface of skin for treatment of actinic keratosis (AK). Actinic keratoses are premalignant lesions considered biologically to be either carcinoma in-situ or squamous intraepidennal neoplasia. AK is the most frequent epidermal tumor and is induced by ultraviolet (UV) radiation, typically from sunlight. Because of its precancerous nature, AK may be considered the most important manifestation of sun-induced skin damage.
In some embodiments, the above described formulations are particularly advantageous for dermal application for a period of time sufficient to obtain a desired therapeutic effect without undesired systemic absorption of the IRM.
EXAMPLES
The following Examples are provided to further describe various IRM formulations and methods according to the invention. The examples, however, are not intended to limit the formulations and methods within the spirit and scope of the invention.
Examples 1-7 and Comparative Example CI Table 1 summarizes topical formulations made in accordance with the present invention in a percentage weight-by-weight basis.
TABLE 1
CD o
Figure imgf000062_0001
The formulations set forth in Table 1 were prepared in the following manner: Oil phase preparation: 2-methyl-l-(2-methylpropyl)-lH-imidazo[4,5-c] [l,5]naphthyridin-4-amine (IRM compound 1) was dissolved in isostearic acid and isopropyl myristate, with heat if necessary. Carbomer 974P was then dispersed in the oil phase. Water phase preparation: Edetate disodium was dissolved in the water.
Methylparaben and propylparaben were dissolved in propylene glycol and the solution was subsequently added to the water phase. Poloxamer 188 was then added to the water phase and mixed until dissolved.
Phase combination: The oil phase was added to the water phase at ambient conditions. The emulsion was then homogenized. After homogenization, sodium hydroxide solution
(20%) w/w) was added and the resulting cream was mixed until smooth and uniform. The pH of the cream was measured and a pH adjustment was made with additional sodium hydroxide solution, if necessary, to meet the in-process target pH of 5.
Formulations containing 2-methyl-l -(2-methylpropyl)-lH-imidazo[4,5-c] [l,5]naphthyridin-4-amine (IRM Compound 1) were tested for their ability to induce increases in cytokine concentrations in rats following topical application. This study was undertaken to evaluate cytokine induction following a single dosing of various strengths and timepoints or a multiple vs. single dosing of IRM Compound 1. The formulations described above were tested by examining tissue and serum concentrations of TNF-α, MCP-1 (monocyte chemoattractant protein- 1) and IFN-α cytokines following drug treatment.
Female CD hairless rats (Charles River Laboratories, Wilmington, MA) weighing 200-250 grams were used in all studies. Animals were randomized to treatment groups and dosed five per treatment group.
The rats were acclimated to collars around the neck on two consecutive days prior to actual dosing. The rats were collared before dosing to prevent ingestion of the drug, and were then dosed topically with 50 μL of active cream or the appropriate placebo on right flank and then housed individually following dosing. At various times following dosing, the rats were anesthetized and blood was collected by cardiac puncture. Blood was allowed to clot at room temperature and serum was separated from the clot via centrifugation and stored at -20 °C until it was analyzed for cytokine concentrations. Following blood collection, the rats were euthanized and their skins removed. Tissue from both treated site (at) and contralateral site (away) were obtained using an 8 mm punch biopsy, weighed, placed in a sealed 1.8 ml cryovial and flash frozen in liquid nitrogen. The frozen tissue sample was then suspended in 1.0 mL RPMI medium (Celox, Hopkins, MN) containing 10%> fetal bovine serum (Sigma, St. Louis, MO), 2 mM L-glutamine, penicillin streptomycin, and 2-mercaptoethanol (RPMI complete) combined with a protease inhibitor cocktail set III (Calbiochem, San Diego, CA). The tissue was homogenized using a Tissue Tearor™ (Biospec Products, Bartlesville, OK) for approximately 1 minute. The tissue suspension was then centrifuged at 2000 rpm for 10 minutes under refrigeration to pellet debris, and the supernatant collected and stored at -20 °C until analyzed for cytokine concentrations.
ELISAs for rat MCP-1 were purchased from BioSource Intl. (Camarillo, CA) and rat TNF-α were purchased from BD Pharmingen (San Diego, CA) and performed according to manufacturer's specifications. Results for both TNF-α, and MCP-1 were expressed in pg/200 mg tissue or pg/ml serum. The sensitivity of the TNF-α ELISA was 31.2 pg/ml and of the
MCP-1 ELISA was 11.7 pg/ml. IFN-α concentrations in both serum and skin tissue were determined using a bioassay that measured inhibition of the viral cytopathic effect of vesicular stomatitis virus on rat LMS-C2 fibroblast cells as previously described (Reiter, M. J., Testennan, T. L., Miller, R. L., Weeks, C. E., and Tomai, M. A. (1994) "Cytokine Induction in Mice by the Immunomodulator Imiquimod." J. Leukocyte Biol. 55, 234-240). IIT
Research Institute, Chicago IL, performed these assays. Results for IFN-α concentrations were normalized to a standard reference rat IFN-α, preparation with results being reported in U/mL and are normalized per mg of tissue.
The data shown below in Tables 2-4 are from three separate experiments and analyzed to 1) measure pharmacokinetics by full time course, 2) measure dose response and 3) measure multiple vs. single dosing.
In order to determine the kinetics of local and systemic cytokine production following local administration of IRM Compound 1, the full time course study (Study 1 with results in Table 2) was done by topically dosing rats with the topical cream formulation of Example 7. Serum and tissue samples were taken at 1, 2, 4, 8, 16, 24 and 48 hours post dose. Multiple cytokines (MCP-1, TNF-α and IFN-α) were analyzed separately.
With the tissue data, for each hour measured, a paired t-test (used to eliminate within subject variability) analyzed the difference between treated tissue and control tissue from the same animal. A p-value less than alpha=0.05 indicated a statistically significant difference between the treated and control tissue at that hour. The data are presented in Table 2.
Table 2. Cytokine Concentrations in Rat Serum and Dermal Tissue Following Application of the Topical Formulation of Example 7 Full Time Course21
Figure imgf000066_0001
aFemale hairless CD rats were dosed topically with cream formulated Compound 1. bTNF-α and MCP-1 were measured by ELISA. IFN-α was measured by bioassay. Results are presented in pg/ml for serum samples and pg/200 mg tissue for tissue samples and represent the mean of five animals + SEM.
°Indicates p<0.05 when compared to either placebo for serum samples or the difference between treated tissue and control tissue from the same animal. A multiple dose study was done to monitor effects of a multiple dose regimen (Study 2 with results shown in Table 3). Rats were dosed two times a week for six hours for three weeks with topical cream formulation of Example 5. Placebo (Comparative Example CI) and single dosed rats were done for comparison and done simultaneously with the last dosing of the multiple dose set. Serum and tissue samples were taken at 8 and 24 hours post dose and analyzed for MCP-1.
An analysis identical to that of Study 1 was performed for Study 2. This data set was broken up by treatment (multiple- or single-use) and time point prior to analysis. Again, placebo data were recorded only at the 8-hour time point for single use, but were used to compare placebo to every treatment and time point combination separately. The results are set forth in Table 3 below.
Table 3. Cytokine Concentrations in Rat Serum and Dermal Tissue Following Topical Application of the Topical Cream Formulation of Example 5 Multiple vs. Single Dosea
Figure imgf000068_0001
aFemale hairless CD rats were dosed topically with cream formulated Compound 1. b MCP-1 was measured by ELISA. Results are presented in pg/ml for serum samples and pg/200 mg tissue for tissue samples and represent the mean of five animals + SEM. °Indicates p<0.05 when compared to either placebo for serum samples or the difference between treated tissue and control tissue from the same animal.
A dose response study (Study 3 with results shown in Table 4) was perfonned by dosing with the topical cream formulations of Examples 3-5 and 7, containing various concentrations of IRM Compound 1. Serum and tissue samples were taken at 8 and 24 hours post dose and analyzed for MCP-1. The studies tested topical delivery of creams comprising IRM Compound 1 for its ability to affect a local MCP-1 induction at four concentrations.
Serum data compared active treatment to placebo (Comparative Example CI) separately at each specified time point. Note that the placebo group was only measured at 24 hours post dose and these observations were compared to each time point for the active group. Table 4. Cytokine Concentrations in Rat Serum and Dermal Tissue Following Topical Application of the Formulations of Examples 3-5 and 7 a
Figure imgf000069_0001
a- Female hairless CD rats were dosed topically with cream formulated Compound 1.
MCP-1 was measured by ELISA. Results are presented in pg/ml for serum samples and pg/200 mg tissue for tissue samples and represent the mean of five animals + SEM. cIndicates p<0.05 when compared to either placebo for serum samples or the difference between treated tissue and control tissue from the same animal.
Examples 8-13
Table 5 summarizes topical formulations made in accordance with the present invention in a percentage weight-by-weight basis. TABLES
Figure imgf000070_0001
The formulations set forth in Table 5 were prepared in the following manner: Oil phase preparation: N-[4-(4-Amino-2-butyl-lH-imidazo[4,5-c] [l,5]naphthyridin- l-yl)butyl]-N'-cyclohexylurea (IRM Compound 2) was dissolved in isostearic acid and isopropyl myristate, with heat if necessary. Carbomer 974P was then dispersed in the oil phase.
Water phase preparation: Edetate disodium was dissolved in the water. Methylparaben and propylparaben were dissolved in propylene glycol, and the solution was subsequently added to the water phase. Poloxamer 188 was then added to the water phase and mixed until dissolved. Phase combination: The oil phase was added to the water phase at ambient conditions.
The emulsion was then homogenized. After homogenization, sodium hydroxide solution (20%) w/w) was added and the resulting cream was mixed until smooth and uniform. The pΗ of the cream was measured, and a pΗ adjustment was made with additional sodium hydroxide solution, if necessary, to meet the in-process target pΗ of 5. Formulations containing N-[4-(4-Amino-2 -butyl- lH-imidazo[4,5- c][l,5]naphthyridin-l-yl)butyl]-N'-cyclohexylurea (IRM Compound 2) were tested for their ability to induce increases in cytokine concentrations in rats following topical application. This study was undertaken to evaluate cytokine induction following a single dosing of various strengths and timepoints or a multiple vs. single dosing of IRM Compound 2. The formulations described above were tested by examining tissue and serum concentrations of
TNF-α, MCP-1 and IFN-α following drug treatment as described in Examples 1-7.
The data shown below in Tables 6-8 are from three separate experiments and analyzed to 1) measure pharmacokinetics by full time course, 2) measure dose response and 3) measure multiple vs. single dosing. In order to determine the kinetics of local and systemic cytokine production following local administration of IRM Compound 2, the full time course study (Study 1 with results in Table 6) was done by topically dosing rats with the topical cream formulation of Example 11 as described in Examples 1-7. The data are presented in Table 6. Table 6. Cytokine Concentrations in Rat Serum and Dennal Tissue Following Application of the Topical Formulation of Example 11 Full Time Coursea
Figure imgf000072_0001
aFemale hairless CD rats were dosed topically with cream formulated Compound 2. bTNF-α and MCP-1 were measured by ELISA. IFN-α was measured by bioassay. Results are presented in pg/ml for serum samples and pg/200 mg tissue for tissue samples and represent the mean of five animals + SEM. cIndicates p<0.05 when compared to either placebo for serum samples or the difference between treated tissue and control tissue from the same animal. A multiple dose study was done to monitor effects of a multiple dose regimen (Study 2 with results shown in Table 7). Rats were dosed two times a week for six hours for three weeks with topical cream formulation of Example 10. Placebo (Comparative Example CI) and single dosed rats were done for comparison and done simultaneously with the last dosing of the multiple dose set. Serum and tissue samples were taken at 16 and 24 hours post dose and analyzed for MCP-1.
An analysis identical to that of Study 1 was performed for Study 2. This data set was broken up by treatment (multi or single use) and time point prior to analysis. Again, placebo data were recorded only at the 16-hour time point for single use, but were used to compare placebo to every treatment and time point combination separately. The results are set forth in
Table 7 below.
Table 7. Cytokine Concentrations in Rat Serum and Dermal Tissue Following Topical Application of the Topical Cream Formulation of Example 10 Multiple vs. Single Dosea
Figure imgf000074_0001
aFemale hairless CD rats were dosed topically with cream formulated Compound 2. b MCP-1 was measured by ELISA. Results are presented in pg/ml for serum samples and pg/200 mg tissue for tissue samples and represent the mean of five animals + SEM. °lndicates p<0.05 when compared to either placebo for serum samples or the difference between treated tissue and control tissue from the same animal.
A dose response study (Study 3 with results shown in Table 8) was performed by dosing with the topical cream formulations of Examples 8-11, containing various concentrations of IRM Compound 2. Serum and tissue samples were taken at 16 and 24 hours post dose and analyzed for MCP-1. The studies tested topical delivery of creams comprising IRM Compound 2 for its ability to affect a local MCP-1 induction at four concentrations.
Serum data compared active treatment to placebo (Comparative Example CI) separately at each specified time point. Note that the placebo group was only measured at 16 hours post dose and these observations were compared to each time point for the active group. Table 8. Cytokine Concentrations in Rat Serum and Dermal Tissue Following Topical Application of the Formulations of Examples 8-11 a
Figure imgf000075_0001
Female hairless CD rats were dosed topically with cream formulated Compound 2. b MCP-1 was measured by ELISA. Results are presented in pg/ml for serum samples and pg/200 mg tissue for tissue samples and represent the mean of five animals + SEM. °hιdicates p<0.05 when compared to either placebo for serum samples or the difference between treated tissue and control tissue from the same animal.
Examples 14 - 18
Table 9 summarizes topical formulations made in accordance with the present invention on a percentage weight-by-weight basis. Table 9
Figure imgf000076_0001
**Available under the trade name Crodamol GTCC-PN from Croda, Inc, Parsippany, NJ
Examples 19 - 24
Table 10 summarizes topical formulations made in accordance with the present invention on a percentage weight-by-weight basis. Table 10
Figure imgf000077_0001
The formulations described in Tables 9 and 10 were prepared using the following general method:
Oil phase preparation:
The IRM compound was dissolved in isostearic acid and diisopropyl dimer dilinoleate (or caprylic/capric acid triglyceride) with heat if necessary. Water phase preparation:
Edetate disodium was dissolved in the water. Poloxamer 188 was then added to the water phase and mixed until dissolved. Carbomer 980 was then added to the water phase and mixed until the carbomer was fully dispersed and hydrated. Methylparaben and propylparaben were dissolved in diethylene glycol monoethyl ether and the solution was subsequently added to the water phase.
Phase combination:
The water phase was added to the oil phase at ambient conditions. The emulsion was then mixed at high speed or homogenized. After homogenization, sodium hydroxide solution (20%) w/w) was added and the resulting cream was mixed until smooth and uniform. The pH of the cream was measured and a pH adjustment was made with additional sodium hydroxide solution, if necessary, to meet the in-process target pH of 5.
Examples 25 - 28 Table 11 summarizes topical formulations made in accordance with the present invention on a percentage weight-by-weight basis.
Table 11
Figure imgf000079_0001
Examples 29 - 135
Topical creams containing the IRM compounds listed in Table 12 were prepared using the general methods described above for Examples 1 - 24. Each IRM was formulated into one or more of the model formulations shown in Tables 13 and 14. Table 15 summarizes the topical creams that were prepared. Table 12
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
*Qsto 100
Table 14
Figure imgf000083_0001
sto 100
Table 15
Figure imgf000083_0002
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
The topical creams of Examples 29 -135 were tested using the test method described below. The results are shown in Table 16 below where each value is the mean of the values from the 3 rats in the treatment group.
SINGLE DOSE MCP-1 INDUCTION TEST METHOD Female CD hairless rats (Charles River Laboratories, Wilmington, MA) weighing 200-250 grams are used. Animals are randomized to treatment groups and dosed three per treatment group.
The rats are acclimated to collars around the neck on two consecutive days prior to actual dosing. A 50 μL dose of active cream or the appropriate placebo is applied to the right flank and gently rubbed into the skin of the rat. The rats are then collared and housed individually to prevent ingestion of the drug. At selected post treatment time points, the rats are anesthetized, and blood (3 mis) is collected by cardiac puncture. Blood is allowed to clot at room temperature. Serum is separated from the clot via centrifugation, and stored at -20°C until it is analyzed for MCP-1 concentration. Following blood collection, the rats are euthanized, and their skins removed. Tissue samples (4 from each site) from both the treated site and contralateral site (untreated) are obtained using an 8 mm punch biopsy, weighed, placed in a sealed 1.8 ml cryovial, and flash frozen in liquid nitrogen. The frozen tissue sample is then suspended in 1.0 mL RPMI medium (Celox, Hopkins, MN) containing 10%) fetal bovine serum (Sigma, St. Louis, MO), 2 mM L-glutamine, penicillin streptomycin, and 2-mercaptoethanol (RPMI complete) combined with a protease inhibitor cocktail set III (Calbiochem, San Diego, CA). The tissue is homogenized using a Tissue Tearor™ (Biospec Products, Bartlesville, OK) for approximately 1 minute. The tissue suspension is then centrifuged at 2000 rpm for 10 minutes under refrigeration to pellet debris, and the supernatant is collected and stored at -20°C until analyzed for MCP-1 concentration.
ELISAs for rat MCP-1 are purchased from BioSource Intl. (Camarillo, CA) and performed according to manufacturer's specifications. Results are expressed in pg/ml, the values for the tissue samples are normalized per 200 mg of tissue. The sensitivity of the MCP-1 ELISA is 12 pg/ml.
Table 16
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
<£>
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000096_0002
Figure imgf000097_0001
Figure imgf000098_0001
*MCP-1 concentration was not measured
**MCP-1 concentration is for the treated site.
***The cream of Example 82 was used in 2 separate experiments
Examples 136 - 140
Table 17 summarizes topical formulations made in accordance with the present invention on a percentage weight-by-weight basis.
Figure imgf000099_0001
The topical creams of Examples 136 -140 were tested using the test method described below. The results are shown in Table 18 below where each value is the mean of the values from the 3 rats in the treatment group. "Normal animals" did not receive any treatment.
SINGLE DOSE CYTOKINE INDUCTION TEST METHOD Female CD hairless rats (Charles River Laboratories, Wilmington, MA) weighing 200-250 grams are used. Animals are randomized to treatment groups and dosed three per treatment group. The rats are acclimated to collars around the neck on two consecutive days prior to actual dosing. A 50 μL dose of active cream is applied to the right flank and gently rubbed into the skin of the rat. The rats are then collared and housed individually to prevent ingestion of the drug. At 6 hours post treatment, the rats are anesthetized, and blood (3 mis) is collected by cardiac puncture. Blood is allowed to clot at room temperature, serum is separated from the clot via centrifugation, and stored at
-20°C until it is analyzed for cytokine concentrations.
Following blood collection, the rats are euthanized, and their skins removed. Tissue samples (4 from each site) from both the treated site and contralateral site (untreated) are obtained using an 8 mm punch biopsy, weighed, placed in a sealed 1.8 ml cryovial, and flash frozen in liquid nitrogen. The frozen tissue sample is then suspended in 1.0 mL RPMI medium (Celox, Hopkins, MN) containing 10%> fetal bovine serum (Sigma, St. Louis, MO), 2 mM L-glutamine, penicillin/streptomycin, and 2-mercaptoethanol (RPMI complete) combined with a protease inhibitor cocktail set III (Calbiochem, San Diego, CA). The tissue is homogenized using a Tissue Tearor™ (Biospec Products, Bartlesville, OK) for approximately 1 minute. The tissue suspension is then centrifuged at 2000 rpm for 10 minutes under refrigeration to pellet debris. The supernatant is collected and stored at -20°C until analyzed for cytokine concentrations.
ELISAs for rat MCP-1 are purchased from BioSource Intl. (Camarillo, CA) and rat TNF-α are purchased from BD Pharmingen (San Diego, CA) and performed according to manufacturer's specifications. Results are expressed in pg/ml, the values for the tissue samples are nonnalized per 200 mg of tissue. The sensitivity of the
MCP-1 ELISA is 12 pg/ml and the sensitivity of the TNF-α ELISA is 31 pg/ml.
Table 18
o o
Figure imgf000102_0001

Claims

What is Claimed is:
1. A pharmaceutical formulation comprising: an immune response modifier (IRM) compound selected from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2- bridged imidazoquinoline amines, thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms; and a hydrophilic viscosity enhancing agent selected from cellulose ethers and carbomers.
2. The formulation according to claim 1 wherein the formulation further comprises a preservative system and an emulsifier.
3. The formulation according to claim 1 wherein the hydrophobic, aprotic component has a hydrophilic lipophilic balance of less than 2.
4. The formulation according to claim 1 wherein the hydrophobic, aprotic component has a pKa greater than 14.2.
5. The formulation according to claim 1 wherein the ratio of the hydrophobic, aprotic component to the fatty acid is 0.025:1 to 600:1.
6. The formulation according to claim 1 wherein the combined weight percent of the hydrophobic, aprotic component and the fatty acid is 2 to 50.
7. The formulation according to claim 1 wherein the fatty acid is isostearic acid.
8. The formulation according to claim 1 wherein the hydrophobic, aprotic component is selected from aprotic fatty acid esters, hydrocarbons of 8 or more carbon atoms, and waxes.
9. The formulation according to claim 8 wherein the aprotic fatty acid ester is isopropyl myristate, isopropyl palmitate, diisopropyl dimer dilinoleate, caprylic/capric triglyceride, cetyl esters wax, or a combination thereof.
10. The formulation according to claim 8 wherein the hydrocarbon of 8 or more carbon atoms is mineral oil or petrolatum.
11. The formulation according to claim 1 wherein the hydrophilic viscosity enhancing agent comprises a carbomer.
12. The formulation according to claim 2 wherein the preservative system comprises methylparaben at 0.01 to 0.5%> w/w of the formulation and propylparaben at 0.01 to 0.5%o w/w of the formulation.
13. The formulation according to claim 2 wherein the preservative system comprises methylparaben at 0.01 to 0.5%> w/w of the formulation and ethylparaben at 0.01 to 0.5%> w/w of the formulation.
14. The formulation according to claim 2 wherein the preservative system comprises iodopropynyl butylcarbamate.
15. The formulation according to claim 2 wherein the preservative system comprises iodopropynyl butylcarbamate and one or more of methylparaben, ethylparaben, propylparaben, or phenoxyethanol.
16. The formulation according to claim 2 wherein the preservative system comprises iodopropynyl butylcarbamate, methylparaben, and ethylparaben.
17. The formulation according to claim 2 wherein the preservative system comprises phenoxyethanol and one or both of methylparaben and ethylparaben.
18. The formulation according to claim 2 wherein the preservative system comprises a preservative enhancing solubilizer.
19. The formulation according to claim 18 wherein the preservative enhancing solubilizer comprises diethylene glycol monoethyl ether, propylene glycol or a combination thereof.
20. The formulation of claim 2 comprising:
(a) 0.001 to 5% w/w 2-methyl-l-(2-methylpropyl)-lH-imidazo[4,5-c] [l,5]naphthyridin-4-amine,
N-[4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-N'-cyclohexylurea, 1 -(2-methylpropyl)- 1 H-imidazo [4,5-c] qumolin-4-amine, 2-butyl-l-(2-methylpropyl)-lH-imidazo[4,5-c][l,8]naphthyridin-4-amine, l-(2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine, 2-methylthiazolo [4,5-c] quinolin-4-amine,
2-ethoxymethyl-l-phenylmethyl-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine, 2-ethylthiazolo[4,5-c]quinolin-4-amine,
4-amino-2-butyl-α,α-dimethyl-lH-imidazo[4,5-c][l,5]naphthyridine-l-ethanol, 1 - {2-[3-(3-pyridyl)propoxy]ethyl} -lH-imidazo[4,5-c]quinolin-4-amine, 1 -(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine,
1 - [(R)- 1 -phenylethyl] - 1 H-imidazo [4, 5 -c] [ 1 , 5 ]naphthyridin-4-amine,
1 - {2-[3-(l ,3 -thiazol-2-yl)propoxy] ethyl} -lH-imidazo [4,5-c] quinolin-4-amine, l-[2-(pyridin-4-ylmethoxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine, N-[3-(4-amino-2-methyl-lH-imidazo[4,5-c]quinolin-l-yl)propyl] cyclohexanecarboxamide,
2-butyl-l-{2-[(l-methylethyl)sulfonyl]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine,
N-{2-[4-amino-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethyl} ethanesulfonamide,
N-{2-[4-amino-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethyl} propanamide,
1 - [2-(methylsulfonyl)ethyl] -2-propyl- lH-imidazo [4,5 -c]quinolin-4-amine,
2-ethyl-l-{4-[(l-methylethyl)sulfonyl]butyl}-lH-imidazo[4,5-c]quinolin-4-amine, 2-ethyl-l-[4-(ethylsulfonyl)butyl]-lH-imidazo[4,5-c]quinolin-4-amine,
N-{3-[4-amino-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]propyl} cyclopentanecarboxamide, l-(2-methylpropyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine,
8,9,10,11 -tetrahydropyrido[ 1 ' ,2' : 1 ,2]imidazo[4,5-c]quinolin-6-amine, 4-amino-α,α,2-trimethyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinoline-l-ethanol,
2-hydroxymethyl- 1 -(2-methylpropyl)-6,7,8,9-tetrahydro- lH-imidazo [4,5-c] quinolin-4-amine,
2-butyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine, or a combination thereof; (b) 0.05 to 40% w/w isostearic acid;
(c) 1 to 30%) w/w hydrophobic, aprotic component;
(d) 0.5 to 10%) w/w emulsifier;
(e) 0.01 to 30%) w/w preservative system; and
(f) 0.1 to 10% carbomer.
21. The formulation of claim 20 comprising:
(a) 0.03 to 3% w/w 2-methyl-l -(2-methylpropyl)- 1 H-imidazo [4,5-c] [ 1 ,5]naphthyridin-4-amine, N-[4-(4-amino-2-butyl- lH-imidazo[4,5-c] [ 1 ,5]naphthyridin- 1 - yl)butyl]-N'-cyclohexylurea, 2-butyl-l-{2-[(l-methylethyl)sulfonyl]ethyl}-lH-imidazo[4,5- c]quinolin-4-amine,or a combination thereof; (b) 3 to 25%o w/w isostearic acid;
(c) 3 to 15%) w/w hydrophobic, aprotic component;
(d) 0.75 to 3.5% w/w emulsifier;
(e) 0.1 to 25%> w/w preservative system; and (f) 0.5 to 5%> w/w carbomer.
22. A method of treating a dermal associated condition, the method comprising a step of: applying to skin a formulation comprising an immune response modifier (IRM) selected from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2- bridged imidazoquinoline amines, thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms; and a hydrophilic viscosity enhancing agent selected from cellulose ethers and carbomers.
23. The method according to claim 22 wherein the ratio of the hydrophobic, aprotic component to the fatty acid is 0.025:1 to 600:1.
24. The method according to claim 22 wherein the combined weight percent of the hydrophobic, aprotic component and the fatty acid is 2 to 50.
25. The method according to claim 22 wherein the hydrophobic, aprotic component is selected from the group consisting of aprotic fatty acid esters, hydrocarbons of 8 or more carbon atoms, and waxes.
26. The method according to claim 25 wherein the aprotic fatty acid ester is isopropyl myristate, isopropyl palmitate, diisopropyl dimer dilinoleate, caprylic/capric triglyceride, cetyl esters wax, or combinations thereof.
27. The method according to claim 22 wherein the hydrophilic viscosity enhancing agent comprises a carbomer.
28. The method according to claim 22 wherein the topical formulation further comprises: a preservative system; and an emulsifier.
29. The method according to claim 22 wherein the IRM is 2-methyl-l-(2-methylpropyl)- lH-imidazo[4,5-c] [l,5]naphthyridin-4-amine, N-[4-(4-amino-2-butyl-lH-imidazo[4,5- c] [ 1 ,5]naphthyridin- 1 -yl)butyl] -N' -cyclohexylurea, 1 -(2-methylpropyl)- 1 H-imidazo[4,5- c]quinolin-4-amine, 2-butyl- 1 -(2-methylpropyl)- 1 H-imidazo [4,5-c] [ 1 ,8]naphthyridin-4-amine, l-(2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine,
2-methylthiazolo[4,5-c]quinolin-4-amine,
2-ethoxymethyl- 1 -phenylmethyl- 1 H-imidazo [4, 5 -c] [ 1 , 5]naphthyridin-4-amine, 2-ethylthiazolo[4,5-c]quinolin-4-amine, 4-amino-2-butyl-α,α-dimethyl- 1 H-imidazo [4,5-c] [ 1 ,5]naphthyridine- 1 -ethanol, l-{2-[3-(3-pyridyl)propoxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine, l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine, 1 -[(R)- 1 -phenylethyl]-lH-imidazo[4,5-c] [ 1 ,5]naphthyridin-4-amine, l-{2-[3-(l,3-thiazol-2-yl)propoxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine, l-[2-(pyridin-4-ylmethoxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine, N-[3-(4-amino-2-methyl-lH-imidazo[4,5-c]quinolin-l-yl)propyl] cyclohexanecarboxamide, 2-butyl-l-{2-[(l-methylethyl)sulfonyl]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine, N-{2-[4-amino-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethyl} ethanesulfonamide,
N-{2-[4-amino-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethyl} propanamide, l-[2-(methylsulfonyl)ethyl]-2-propyl-lH-imidazo[4,5-c]quinolin-4-amine,
2-ethyl-l-{4-[(l-methylethyl)sulfonyl]butyl}-lH-imidazo[4,5-c]quinolin-4-amine,
2-ethyl- 1 - [4-(ethylsulfonyl)butyl] - 1 H-imidazo [4,5-c] quinolin-4-amine,
N-{3-[4-amino-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]propyl} cyclopentanecarboxamide, l-(2-methylpropyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine,
8,9,10,11 -tetrahydropyrido [1 ' ,2' : 1 ,2]imidazo[4,5-c]quinolin-6-amine,
4-amino-α,α,2-trimethyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinoline-l-ethanol,
2-hydroxymethyl- 1 -(2-methylpropyl)-6,7,8,9-tetrahydro- lH-imidazo [4,5-c] quinolin-4-amine, 2-butyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine, or a combination thereof.
30. The method according to claim 22 wherein the dermal associated condition is selected from actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts.
31. The method according to claim 30 wherein the IRM is 2-methyl-l-(2- methylpropyl)-lH-imidazo[4,5-c] [l,5]naphthyridin-4-amine, N-[4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-N'-cyclohexylurea, 1 -(2-methylpropyl)- 1 H-imidazo[4,5-c]quinolin-4-amine,
2-butyl-l-(2-methylpropyl)-lH-imidazo[4,5-c][l,8]naphthyridin-4-amine, l-(2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine,
2-methylthiazolo [4,5-c] quinolin-4-amine,
2-ethoxymethyl-l-phenylmethyl-lH-imidazo[4,5-c][l,5]naphthyridin-4- amine, 2-ethylthiazolo[4,5-c]quinolin-4-amine, 4-amino-2-butyl-α,α-dimethyl-lH-imidazo[4,5-c][l,5]naphthyridine-l-ethanol, l-{2-[3-(3-pyridyl)propoxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine, l-(2-phenoxyethyl)-lH-imidazo[4,5-c]quinolin-4-amine,
1-[(R)- 1 -phenylethyl]- lH-imidazo[4,5-c] [ 1 ,5]naphthyridin-4-amine, l-{2-[3-(l,3-thiazol-2-yl)propoxy]ethyl}-lH-imidazo[4,5-c]quinolin-4-amine, l-[2-(pyridin-4-ylmethoxy)ethyl]-lH-imidazo[4,5-c]quinolin-4-amine,
N- [3 -(4-amino-2 -methyl- 1 H-imidazo [4,5-c] quinolin- 1 -yl)propyl] cyclohexanecarboxamide,
2-butyl- 1 - {2-[(l -methylethyl)sulfonyl] ethyl} - lH-imidazo[4,5-c]quinolin-4-amine, N-{2-[4-amino-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]ethyl} ethanesulfonamide,
N- {2-[4-amino-2-(ethoxymethyl)- 1 H-imidazo [4,5-c] quinolin- 1 -yl] ethyl} propanamide, l-[2-(methylsulfonyl)ethyl]-2-propyl-lH-imidazo[4,5-c]quinolin-4-amine, 2-ethyl- 1 - {4-[(l -methylethyl)sulfonyl]butyl} - lH-imidazo[4,5-c]quinolin-4-amine,
2-ethyl-l-[4-(ethylsulfonyl)butyl]-lH-imidazo[4,5-c]quinolin-4-amine,
N-{3-[4-amino-2-(ethoxymethyl)-lH-imidazo[4,5-c]quinolin-l-yl]propyl} cyclopentanecarboxamide, l-(2-methylpropyl)-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-4-amine, 8,9,10,1 l-tetrahydiOpyrido[r,2':l,2]imidazo[4,5-c]quinolin-6-amine,
4-amino-α,α,2-trimethyl-6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinoline-l-ethanol,
2-hydroxymethyl-l-(2-methylpropyl)-6,7,8,9-tetrahydro-
1 H-imidazo [4,5-c] quinolin-4-amine,
2-butyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine, or a combination thereof.
32. The method according to claim 30 wherein the formulation further comprises a preservative system and an emulsifier.
33. The method according to claim 32 wherein the preservative system comprises methylparaben at 0.01 to 0.5%o w/w of the formulation and propylparaben at 0.01 to 0.5%) w/w of the formulation.
34. The method according to claim 32 wherein the preservative system comprises methylparaben at 0.01 to 0.5%> w/w of the formulation and ethylparaben at 0.01 to 0.5%) w/w of the formulation.
35. The method according to claim 32 wherein the preservative system comprises iodopropynyl butylcarbamate.
36. The method according to claim 32 wherein the preservative system comprises iodopropynyl butylcarbamate and one or more of methylparaben, ethylparaben, propylparaben, or phenoxyethanol.
37. The method according to claim 32 wherein the preservative system comprises iodopropynyl butylcarbamate, methylparaben, and ethylparaben.
38. The method according to claim 32 wherein the preservative system comprises phenoxyethanol and one or both of methylparaben and ethylparaben.
39. The method according to claim 32 wherein the preservative system comprises a preservative enhancing solubilizer.
40. The method according to claim 39 wherein the preservative enhancing solubilizer comprises diethylene glycol monoethyl ether, propylene glycol or a combination thereof.
41. A method for delivering an immune response modifier (IRM) to a dermal surface, the method comprising the steps of: selecting a formulation comprising: (a) an immune response modifier selected from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2- bridged imidazoquinoline amines, thiazoloquinoline amines, oxazoloquinoline amines, thiazolopyridine amines, oxazolopyridine amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines;
(b) a fatty acid;
(c) a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms; and
(d) a hydrophilic viscosity enhancing agent selected from cellulose ethers and carbomers; and applying the selected topical formulation to the dermal surface.
42. A pharmaceutical formulation comprising: an immune response modifier (IRM) compound selected from the group consisting of imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms.
43. The formulation according to claim 42 wherein the formulation further comprises a preservative system.
44. The formulation according to claim 42 wherein the hydrophobic, aprotic component has a hydrophilic lipophilic balance of less than 2.
45. The fonnulation according to claim 42 wherein the hydrophobic, aprotic component has a pKa greater than 14.2.
46. The formulation according to claim 42 wherein the ratio of the hydrophobic, aprotic component to the fatty acid is 0.025:1 to 600:1.
47. The formulation according to claim 42 wherein the combined weight percent of the hydrophobic, aprotic component and the fatty acid is 2 to 50.
48. The formulation according to claim 42 wherein the fatty acid is isostearic acid.
49. The formulation according to claim 42 wherein the hydrophobic, aprotic component is selected from aprotic fatty acid esters, hydrocarbons of 8 or more carbon atoms, and waxes.
50. The formulation according to claim 49 wherein the aprotic fatty acid ester is isopropyl myristate, isopropyl palmitate, diisopropyl dimer dilinoleate, caprylic/capric triglyceride, cetyl esters wax, or combinations thereof.
51. The formulation of claim 49 wherein the hydrocarbon of 8 or more carbon atoms is mineral oil or petrolatum.
52. The fonnulation according to claim 43 wherein the preservative system comprises methylparaben at 0.01 to 0.5% w/w of the formulation and propylparaben at 0.01 to 0.5%> w/w of the formulation.
53. The fonnulation according to claim 43 wherein the preservative system comprises methylparaben at 0.01 to 0.5%> w/w of the formulation and ethylparaben at 0.01 to 0.5%ι w/w of the formulation.
54. The formulation according to claim 43 wherein the preservative system comprises iodopropynyl butylcarbamate.
I l l
55. The formulation according to claim 43 wherein the preservative system comprises iodopropynyl butylcarbamate and one or more of methylparaben, ethylparaben, propylparaben, or phenoxyethanol.
56. The formulation according to claim 43 wherein the preservative system comprises iodopropynyl butylcarbamate, methylparaben, and ethylparaben.
57. The formulation according to claim 43 wherein the preservative system comprises phenoxyethanol and one or both of methylparaben and ethylparaben.
58. The formulation according to claim 43 wherein the preservative system comprises a preservative enhancing solubilizer.
59. The formulation according to claim 58 wherein the preservative enhancing solubilizer comprises diethylene glycol monoethyl ether, propylene glycol or a combination thereof.
60. The formulation of claim 43 comprising: (a) 0.001 to 5%> w/w imidazonaphthyridine amine, imidazotetrahydronaphthyridme amine, thiazolonaphthyridine amine, or a combination thereof;
(b) 0.05 to 40%) w/w isostearic acid;
(c) 1 to 30%) w/w hydrophobic, aprotic component; and (d) 0.01 to 30%) w/w preservative system.
61. The formulation of claim 43 further comprising an emulsifier and a hydrophilic viscosity enhancing agent.
62. The fonnulation of claim 60 further comprising an emulsifier and a hydrophilic viscosity enhancing agent.
63. The formulation of claim 62 wherein the viscosity enhancing agent comprises a carbomer.
64. The fonnulation of claim 63 comprising:
(a) 0.03 to 3% w/w
2-methyl- 1 -(2-methylpropyl)- 1 H-imidazo [4,5-c] [1,5] naphthyridin-4-amine, N-[4-(4-amino-2-butyl-lH-imidazo[4,5-c][l,5]naphthyridin-l-yl)butyl]-N'-cyclohexylurea,
2-butyl- 1 -(2-methylpropyl)- 1 H-imidazo [4,5-c] [ 1 ,8]naphthyridin-4-amine,
1 -(2-methylpropyl)- 1 H-imidazo [4,5-c] [1 ,5]naphthyridin-4-amine,
2-ethoxymethyl-l-phenylmethyl-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine,
4-amino-2-butyl-α,α-dimethyl-lH-imidazo[4,5-c][l,5]naphthyridine-l-ethanol, 1 -[(R)- 1 -phenylethyl] - 1 H-imidazo[4,5-c] [ 1 ,5]naphthyridin-4-amine,
2-butyl- 1 -(2 -phenoxyethyl)- 1 H-imidazo[4,5-c] [ 1 ,5]naphthyridin-4-amine, or a combination thereof;
(b) 3 to 25%o w/w isostearic acid;
(c) 3 to 15%> w/w hydrophobic, aprotic component; (d) 0.1 to 25%o w/w preservative system;
(e) 0.75 to 3.5%) w/w emulsifier; and
(f) 0.5 to 5%o w/w carbomer.
65. A method of treating a dermal associated condition, the method comprising a step of: applying to skin a formulation comprising an immune response modifier (IRM) chosen from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms.
66. The method according to claim 65 wherein the ratio of the hydrophobic, aprotic component to the fatty acid is 0.025:1 to 600:1.
67. The method according to claim 65 wherein the combined weight percent of the hydrophobic, aprotic component and the fatty acid is 2 to 50.
68. The method according to claim 65 wherein the hydrophobic, aprotic component is selected from the group consisting of aprotic fatty acid esters, hydrocarbons of 8 or more carbon atoms, and waxes.
69. The method according to claim 68 wherein the aprotic fatty acid ester is isopropyl myristate, isopropyl palmitate, diisopropyl dimer dilinoleate, caprylic/capric triglyceride, cetyl esters wax, or combinations thereof.
70. The method according to claim 65 wherein the formulation further comprises: a preservative system; and an emulsifier.
71. The method according to claim 65 wherein the JJRM is 2-methyl- 1 -(2-methylpropyl)-
1 H-imidazo [4,5-c] [l,5]naphthyridin-4-amine, N-[4-(4-amino-2-butyl-lH-imidazo[4,5- c] [ 1 ,5]naphthyridin- 1 -yl)butyl] -N' -cyclohexylurea, 2-butyl-l-(2-methylpropyl)-lH-imidazo[4,5-c][l,8]naphthyridin-4-amine, 1 -(2-methylpropyl)- 1 H-imidazo[4,5-c] [ 1 ,5]naphthyridin-4-amine, 2-ethoxymethyl- 1 -phenylmethyl- 1 H-imidazo [4,5-c] [ 1 ,5]naphthyridin-4-amine,
4-amino-2-butyl-α,α-dimethyl- 1 H-imidazo [4,5-c] [ 1 ,5]naphthyridine- 1 -ethanol, 1 -[(R)- 1 -phenylethyl] - 1 H-imidazo [4,5-c] [ 1 ,5]naphthyridin-4-amine, 2-butyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine, or a combination thereof.
72. The method according to claim 65 wherein the dermal associated condition is actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts.
73. The method according to claim 72 wherein the IRM is 2-methyl- 1 -(2 -methylpropyl)- lH-imidazo[4,5-c] [l,5]naphthyridin-4-amine, N-[4-(4-amino-2-butyl-lH-imidazo[4,5- c] [1 ,5]naphthyridin-l-yl)butyl]-N'-cyclohexylurea, 2-butyl- 1 -(2-methylpropyl)- lH-imidazo[4,5-c] [ 1 ,8]naphthyridin-4-amine, l-(2-methylpropyl)-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine, 2-ethoxymethyl- 1 -phenylmethyl- lH-imidazo[4,5-c] [ 1 ,5]naphthyridin-4-amine, 4-amino-2-butyl-α,α-dimethyl- lH-imidazo[4,5-c] [ 1 ,5]naphthyridine- 1 -ethanol, l-[(R)-l-phenylethyl]-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine, 2-butyl-l-(2-phenoxyethyl)-lH-imidazo[4,5-c][l,5]naphthyridin-4-amine, or a combination thereof.
74. The method according to claim 72 wherein the formulation further comprises: a preservative system; and an emulsifier.
75. The method according to claim 74 wherein the preservative system comprises methylparaben at 0.01 to 0.5%> w/w of the formulation and propylparaben at 0.01 to 0.5% w/w of the formulation.
76. The method according to claim 74 wherein the preservative system comprises methylparaben at 0.01 to 0.5% w/w of the formulation and ethylparaben at 0.01 to 0.5%) w/w of the formulation.
77. The method according to claim 74 wherein the preservative system comprises iodopropynyl butylcarbamate.
78. The method according to claim 74 wherein the preservative system comprises iodopropynyl butylcarbamate and one or more of methylparaben, ethylparaben, propylparaben, or phenoxyethanol.
79. The method according to claim 74 wherein the preservative system comprises iodopropynyl butylcarbamate, methylparaben, and ethylparaben.
80. The method according to claim 74 wherein the preservative system comprises phenoxyethanol and one or both of methylparaben and ethylparaben.
81. The method according to claim 74 wherein the preservative system comprises a preservative enhancing solubilizer.
82. The method according to claim 81 wherein the preservative enhancing solubilizer comprises diethylene glycol monoethyl ether, propylene glycol or a combination thereof.
83. A method for delivering an immune response modifier (IRM) to a dermal surface, the method comprising the steps of: selecting a formulation comprising: (a) an immune response modifier selected from imidazonaphthyridine amines, imidazotetrahydronaphthyridme amines, and thiazolonaphthyridine amines;
(b) at fatty acid;
(c) a hydrophobic, aprotic component miscible with the fatty acid and comprising a hydrocarbyl group of 7 or more carbon atoms; and applying the selected formulation to the dermal surface.
PCT/US2002/038190 2001-11-29 2002-11-27 Pharmaceutical formulations comprising an immune response modifier WO2003045391A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA2467828A CA2467828C (en) 2001-11-29 2002-11-27 Pharmaceutical formulations comprising an immune response modifier
MXPA04005023A MXPA04005023A (en) 2001-11-29 2002-11-27 Pharmaceutical formulations comprising an immune response modifier.
DE60228611T DE60228611D1 (en) 2001-11-29 2002-11-27 PHARMACEUTICAL FORMULATION COMPREHENSIVE A MEDIUM MODIFYING THE IMMUNE RESPONSE
IL16178602A IL161786A0 (en) 2001-11-29 2002-11-27 Pharmaceutical formulations comprising an immune
EP02798470A EP1450804B9 (en) 2001-11-29 2002-11-27 Pharmaceutical formulations comprising an immune response modifier
BR0214566-9A BR0214566A (en) 2001-11-29 2002-11-27 Pharmaceutical formulations comprising an immune response modifier
AU2002363954A AU2002363954B2 (en) 2001-11-29 2002-11-27 Pharmaceutical formulations comprising an immune response modifier
NZ532769A NZ532769A (en) 2001-11-29 2002-11-27 Pharmaceutical formulations comprising an immune response modifier
KR1020047008119A KR100962751B1 (en) 2001-11-29 2002-11-27 Pharmaceutical Formulations Comprising an Immune Response Modifier
DK02798470T DK1450804T3 (en) 2001-11-29 2002-11-27 Pharmaceutical formula rings comprising an immune response modifier
JP2003546893A JP4447914B2 (en) 2001-11-29 2002-11-27 Drugs containing immune response modifiers
IL161786A IL161786A (en) 2001-11-29 2004-05-05 Pharmaceutical formulation comprising an immune response modifier and hydrophobic aprotic component
HRP20040474AA HRP20040474B1 (en) 2001-11-29 2004-05-27 Pharmaceutical formulations comprising an immune response modifier
NO20042714A NO328298B1 (en) 2001-11-29 2004-06-28 Pharmaceutical preparations comprising the immunomodulating compound 2-methyl-1- (2-methylpropyl) -1H-imidazole [4,5-c] [1,5] naphthyridin-4-amine
HK05106305.2A HK1073778A1 (en) 2001-11-29 2005-07-25 Pharmaceutical formulations comprising an immune response modifier

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34060501P 2001-11-29 2001-11-29
US60/340,605 2001-11-29
US37845202P 2002-05-06 2002-05-06
US60/378,452 2002-05-06

Publications (1)

Publication Number Publication Date
WO2003045391A1 true WO2003045391A1 (en) 2003-06-05

Family

ID=26992178

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/038190 WO2003045391A1 (en) 2001-11-29 2002-11-27 Pharmaceutical formulations comprising an immune response modifier

Country Status (20)

Country Link
US (2) US20030199538A1 (en)
EP (1) EP1450804B9 (en)
JP (1) JP4447914B2 (en)
KR (1) KR100962751B1 (en)
CN (1) CN100473384C (en)
AT (1) ATE406164T1 (en)
AU (1) AU2002363954B2 (en)
BR (1) BR0214566A (en)
CA (1) CA2467828C (en)
DE (1) DE60228611D1 (en)
DK (1) DK1450804T3 (en)
ES (1) ES2312659T3 (en)
HK (1) HK1073778A1 (en)
HR (1) HRP20040474B1 (en)
IL (2) IL161786A0 (en)
MX (1) MXPA04005023A (en)
NZ (1) NZ532769A (en)
PL (1) PL210514B1 (en)
RU (1) RU2327460C2 (en)
WO (1) WO2003045391A1 (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797718B2 (en) 2002-06-07 2004-09-28 3M Innovative Properties Company Ether substituted imidazopyridines
US6818650B2 (en) 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
US6888000B2 (en) 2001-12-21 2005-05-03 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6921826B2 (en) 2000-12-08 2005-07-26 3M Innovative Properties Co. Thioether substituted imidazoquinolines
WO2005082334A1 (en) * 2004-02-27 2005-09-09 Hisamitsu Pharmaceutical Co., Inc. Sustained-release cream preparation
US6949649B2 (en) 2000-12-08 2005-09-27 3M Innovative Properties Co. Thioether substituted imidazoquinolines
US6953804B2 (en) 2000-12-08 2005-10-11 3M Innovative Properties Co. Aryl ether substituted imidazoquinolines
US6989389B2 (en) 2000-12-08 2006-01-24 3M Innovative Properties Co. Aryl ether substituted imidazoquinolines
WO2006009826A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
EP1651190A2 (en) * 2003-08-05 2006-05-03 3M Innovative Properties Company Formulations containing an immune response modifier
WO2006071997A2 (en) 2004-12-30 2006-07-06 3M Innovative Properties Company Treatment for cutaneous metastases
US7078523B2 (en) 2000-12-08 2006-07-18 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
WO2006091568A2 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
US7115622B2 (en) 2000-12-08 2006-10-03 3M Innovative Properties Company Amido ether substituted imidazoquinolines
EP1729768A2 (en) * 2004-03-15 2006-12-13 3M Innovative Properties Company Immune response modifier formulations and methods
EP1850850A2 (en) * 2000-12-08 2007-11-07 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US7427629B2 (en) 2002-08-15 2008-09-23 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US7696159B2 (en) 2003-03-25 2010-04-13 Graceway Pharmaceuticals, Llc Treatment for basal cell carcinoma
US7923560B2 (en) 2003-04-10 2011-04-12 3M Innovative Properties Company Delivery of immune response modifier compounds
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
WO2013013055A1 (en) 2011-07-21 2013-01-24 Rubigo Therapeutics, Inc. System for drug delivery and monitoring
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
US8426457B2 (en) 2003-03-13 2013-04-23 Medicis Pharmaceutical Corporation Methods of improving skin quality
US8598196B2 (en) 2008-08-18 2013-12-03 Medicis Pharmaceutical Corporation Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US8642616B2 (en) 2009-07-13 2014-02-04 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US8940755B2 (en) 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US8961477B2 (en) 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US9962453B2 (en) 2013-12-02 2018-05-08 Altimmune Uk Limited Immunogenic compound

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
JP3436512B2 (en) * 1999-12-28 2003-08-11 株式会社デンソー Accelerator device
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
JP2005518433A (en) * 2002-02-22 2005-06-23 スリーエム イノベイティブ プロパティズ カンパニー Methods for reducing and treating UVB-induced immunosuppression
AU2003301052A1 (en) 2002-12-20 2004-07-22 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
CA2517655A1 (en) * 2003-03-07 2004-09-23 3M Innovative Properties Company 1-amino 1h-imidazoquinolines
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
WO2004080293A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
WO2004087049A2 (en) * 2003-03-25 2004-10-14 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
WO2004110992A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company Process for imidazo[4,5-c] pyridin-4-amines
US8211906B1 (en) 2003-08-05 2012-07-03 Scherrer Lawrence C Method of inhibiting growth of neoplastic cells and inhibiting infection by administering an immune enhancer drug
JP2007502288A (en) * 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー Oxime-substituted imidazo-containing compounds
PL1653959T3 (en) * 2003-08-14 2015-10-30 3M Innovative Properties Co Lipid-modified immune response modifiers
EP1660122A4 (en) * 2003-08-25 2007-10-24 3M Innovative Properties Co Immunostimulatory combinations and treatments
EP1658076B1 (en) 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504172A (en) * 2003-09-02 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Methods for treatment of mucosa related symptoms
AU2004270201A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
EP1664342A4 (en) * 2003-09-17 2007-12-26 3M Innovative Properties Co Selective modulation of tlr gene expression
AU2004315876B2 (en) 2003-10-03 2011-05-26 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005041891A2 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
CA2545774A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
WO2005048945A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
US8778963B2 (en) * 2003-11-25 2014-07-15 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
AU2004315771A1 (en) 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
WO2005066172A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co Enhancement of immune responses
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
JP2008505857A (en) * 2004-04-28 2008-02-28 スリーエム イノベイティブ プロパティズ カンパニー Compositions and methods for mucosal vaccination
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
EP1765348B1 (en) * 2004-06-18 2016-08-03 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
EP1786450A4 (en) * 2004-08-27 2009-11-11 3M Innovative Properties Co Hiv immunostimulatory compositions
CA2578975A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
CA2578741C (en) * 2004-09-02 2014-01-14 3M Innovative Properties Company 1-alkoxy 1h-imidazo ring systems and methods
WO2006042254A2 (en) * 2004-10-08 2006-04-20 3M Innovative Properties Company Adjuvant for dna vaccines
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
WO2006074003A2 (en) 2004-12-30 2006-07-13 3M Innovative Properties Company CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
CA2592897A1 (en) * 2004-12-30 2006-07-13 Takeda Pharmaceutical Company Limited 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
CA2594674C (en) 2004-12-30 2016-05-17 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
WO2006084073A2 (en) * 2005-02-04 2006-08-10 Takeda Pharmaceutical Company Limited Aqueous gel formulations containing 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine
CA2602083A1 (en) 2005-02-09 2006-08-09 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
CA2598695A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
EP1850849A2 (en) 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
AU2006223148A1 (en) * 2005-03-14 2006-09-21 3M Innovative Properties Company Method of treating actinic keratosis
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008539252A (en) 2005-04-25 2008-11-13 スリーエム イノベイティブ プロパティズ カンパニー Immune activation composition
US8476292B2 (en) 2005-09-09 2013-07-02 3M Innovative Properties Company Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) * 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
EP1948173B1 (en) 2005-11-04 2013-07-17 3M Innovative Properties Company Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
EP3085373A1 (en) 2006-02-22 2016-10-26 3M Innovative Properties Company Immune response modifier conjugates
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
EP2046121B1 (en) * 2006-07-14 2012-08-22 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
NO343857B1 (en) * 2006-07-18 2019-06-24 Meda Ab Immune Response Modifying Foam Formulations
AU2007279376B2 (en) * 2006-07-31 2012-09-06 Wirra Ip Pty Ltd Immune response modifier compositions and methods
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
WO2008082381A1 (en) * 2006-12-29 2008-07-10 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
WO2008082382A1 (en) * 2006-12-29 2008-07-10 Graceway Pharmaceuticals, Inc. Packaging for 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine containing formulation
AU2009228769C1 (en) * 2008-03-24 2014-11-06 BioNTech SE Novel substituted imidazoquinolines
KR20110090892A (en) * 2008-10-31 2011-08-10 모베르그 데르마 아베 Topical composition comprising a combination of at least two penetration enhancing agents
MX346455B (en) 2008-12-19 2017-03-21 Medicis Pharmaceutical Corp Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis.
CN104940225A (en) * 2009-08-24 2015-09-30 谭国梁 Medicine capable of dissolving and eliminating lesion tissues and pathogens
HUE033901T2 (en) 2010-08-17 2018-01-29 3M Innovative Properties Co Lipidated immune response modifier compound compositions, formulations, and methods
JP6460789B2 (en) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー Heterobifunctional linker having polyethylene glycol segment and immune response modulating complex prepared from the linker
CA2838023C (en) 2011-06-03 2019-08-13 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
AU2014347059B2 (en) * 2013-11-05 2017-09-07 Solventum Intellectual Properties Company Sesame oil based injection formulations
KR102590454B1 (en) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Antibody-Adjuvant Conjugate
EP3554550A1 (en) 2016-12-13 2019-10-23 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
US11306083B2 (en) 2017-12-20 2022-04-19 3M Innovative Properties Company Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595586A (en) * 1985-08-30 1986-06-17 Eli Lilly And Company Moisturizing lotion
US4800076A (en) * 1987-03-13 1989-01-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
WO2000040228A2 (en) * 1999-01-08 2000-07-13 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
WO2002046188A2 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Amido ether substituted imidazoquinolines

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) * 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US5756747A (en) * 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
DK0553202T3 (en) * 1990-10-05 1995-07-03 Minnesota Mining & Mfg Process for the preparation of imidazo (4,5-c) quinoline-4-amines
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
CZ288182B6 (en) * 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
JPH09208584A (en) 1996-01-29 1997-08-12 Terumo Corp Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
CA2268957C (en) * 1996-10-25 2008-04-29 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of th2 mediated and related diseases
US5728732A (en) * 1996-11-27 1998-03-17 Elizabeth Arden Company, Division Of Conopco, Inc. Skin treatment with salicylic acid esters and retinoids
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
EP0894797A4 (en) * 1997-01-09 2001-08-16 Terumo Corp Novel amide derivatives and intermediates for the synthesis thereof
US5939080A (en) * 1997-01-10 1999-08-17 The Procter & Gamble Company Hydrophobic agents and non-polymeric surfactants use in oral care products
TW450810B (en) 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
US6248763B1 (en) * 1998-05-19 2001-06-19 Scivoletto Rosemarie Composition for treating skin conditions
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
JPH11222432A (en) 1998-02-03 1999-08-17 Terumo Corp Preparation for external use containing amide derivative inducing interferon
JPH11255926A (en) 1998-03-13 1999-09-21 Toray Ind Inc Silicone molding and its production
JP2000119271A (en) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
US20020094341A1 (en) 1998-11-03 2002-07-18 Lise W. Jorgensen Skin moisturizer compositions containing a sebum control agent
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (en) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd Arachidonic acid-induced skin disease-treating agent
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
JP4521899B2 (en) 1999-08-27 2010-08-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 Clotamiton-containing skin external solution
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (en) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd Therapeutic agent for arachidonic acid-induced dermatosis
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
EP1360486A2 (en) 2000-12-08 2003-11-12 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
JP2005519849A (en) 2001-06-15 2005-07-07 スリーエム イノベイティブ プロパティズ カンパニー Immune response modifier for the treatment of periodontal disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595586A (en) * 1985-08-30 1986-06-17 Eli Lilly And Company Moisturizing lotion
US4800076A (en) * 1987-03-13 1989-01-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
WO2000040228A2 (en) * 1999-01-08 2000-07-13 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
WO2002046188A2 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Amido ether substituted imidazoquinolines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOLLET J L ET AL: "DEVELOPMENT OF A TOPICALLY ACTIVE IMIQUIMOD FORMULATION", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, NEW YORK, NY, US, vol. 4, no. 1, January 1999 (1999-01-01), pages 35 - 43, XP000900717, ISSN: 1083-7450 *
MILLER R L ET AL: "IMIQUIMOD APPLIED TOPICALLY: A NOVEL IMMUNE RESPONSE MODIFIER AND NEW CLASS OF DRUG", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, vol. 21, no. 1, January 1999 (1999-01-01), pages 1 - 14, XP000900725, ISSN: 0192-0561 *

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
EP1850850A2 (en) * 2000-12-08 2007-11-07 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
EP1850850A4 (en) * 2000-12-08 2011-06-15 3M Innovative Properties Co Compositions and methods for targeted delivery of immune response modifiers
US7214675B2 (en) 2000-12-08 2007-05-08 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6921826B2 (en) 2000-12-08 2005-07-26 3M Innovative Properties Co. Thioether substituted imidazoquinolines
US7132429B2 (en) 2000-12-08 2006-11-07 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US7078523B2 (en) 2000-12-08 2006-07-18 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6949649B2 (en) 2000-12-08 2005-09-27 3M Innovative Properties Co. Thioether substituted imidazoquinolines
US6953804B2 (en) 2000-12-08 2005-10-11 3M Innovative Properties Co. Aryl ether substituted imidazoquinolines
US6989389B2 (en) 2000-12-08 2006-01-24 3M Innovative Properties Co. Aryl ether substituted imidazoquinolines
US7288550B2 (en) 2000-12-08 2007-10-30 3M Innovative Properties Company Thioether substituted imidazoquinolines
US7115622B2 (en) 2000-12-08 2006-10-03 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US7276515B2 (en) 2000-12-08 2007-10-02 Coley Pharmaceutical Group, Inc. Thioether substituted imidazoquinolines
US6924293B2 (en) 2001-12-21 2005-08-02 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6888000B2 (en) 2001-12-21 2005-05-03 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6797718B2 (en) 2002-06-07 2004-09-28 3M Innovative Properties Company Ether substituted imidazopyridines
US7125890B2 (en) 2002-06-07 2006-10-24 3M Innovative Properties Company Ether substituted imidazopyridines
US7427629B2 (en) 2002-08-15 2008-09-23 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
EP2269632A2 (en) 2002-08-15 2011-01-05 3M Innovative Properties Co. Immunostimulatory compositions and methods of stimulating an immune response
US7112677B2 (en) 2002-09-26 2006-09-26 3M Innovative Properties Company 1H-imidazo dimers
US6818650B2 (en) 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
US10105426B2 (en) 2002-12-30 2018-10-23 Trustees Of Dartmouth College Immunostimulatory combinations
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
US8426457B2 (en) 2003-03-13 2013-04-23 Medicis Pharmaceutical Corporation Methods of improving skin quality
US7696159B2 (en) 2003-03-25 2010-04-13 Graceway Pharmaceuticals, Llc Treatment for basal cell carcinoma
US8835394B2 (en) 2003-03-25 2014-09-16 Medicis Pharmaceutical Corporation Treatment for basal cell carcinoma
US7923560B2 (en) 2003-04-10 2011-04-12 3M Innovative Properties Company Delivery of immune response modifier compounds
EP1651190A2 (en) * 2003-08-05 2006-05-03 3M Innovative Properties Company Formulations containing an immune response modifier
EP1651190A4 (en) * 2003-08-05 2009-07-15 3M Innovative Properties Co Formulations containing an immune response modifier
US8221771B2 (en) 2003-08-05 2012-07-17 3M Innovative Properties Company Formulations containing an immune response modifier
US8961477B2 (en) 2003-08-25 2015-02-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8940755B2 (en) 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
JPWO2005082334A1 (en) * 2004-02-27 2007-10-25 久光製薬株式会社 Sustained release cream
WO2005082334A1 (en) * 2004-02-27 2005-09-09 Hisamitsu Pharmaceutical Co., Inc. Sustained-release cream preparation
JP4731472B2 (en) * 2004-02-27 2011-07-27 久光製薬株式会社 Sustained release cream
EP1729768A4 (en) * 2004-03-15 2013-10-30 3M Innovative Properties Co Immune response modifier formulations and methods
JP2007529537A (en) * 2004-03-15 2007-10-25 スリーエム イノベイティブ プロパティズ カンパニー Immune response modulator formulation and method
EP1729768A2 (en) * 2004-03-15 2006-12-13 3M Innovative Properties Company Immune response modifier formulations and methods
WO2006009826A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006071997A2 (en) 2004-12-30 2006-07-06 3M Innovative Properties Company Treatment for cutaneous metastases
EP2394650A1 (en) 2004-12-30 2011-12-14 3M Innovative Properties Co. Use of resiquimod for the treatment of cutaneous metastases
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US10071156B2 (en) 2005-02-04 2018-09-11 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
WO2006091568A2 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
WO2006091568A3 (en) * 2005-02-23 2007-05-31 3M Innovative Properties Co Hydroxyalkyl substituted imidazonaphthyridines
US8343993B2 (en) 2005-02-23 2013-01-01 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
US9271973B2 (en) 2008-08-18 2016-03-01 Medicis Pharmaceutical Corporation Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US8598196B2 (en) 2008-08-18 2013-12-03 Medicis Pharmaceutical Corporation Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
US10238645B2 (en) 2009-07-13 2019-03-26 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US9980955B2 (en) 2009-07-13 2018-05-29 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US9078889B2 (en) 2009-07-13 2015-07-14 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US8642616B2 (en) 2009-07-13 2014-02-04 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US10918635B2 (en) 2009-07-13 2021-02-16 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US11850245B2 (en) 2009-07-13 2023-12-26 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
WO2013013055A1 (en) 2011-07-21 2013-01-24 Rubigo Therapeutics, Inc. System for drug delivery and monitoring
US9962453B2 (en) 2013-12-02 2018-05-08 Altimmune Uk Limited Immunogenic compound
US10434183B2 (en) 2013-12-02 2019-10-08 Altimmune UK Ltd. Immunogenic compound
US10849984B2 (en) 2013-12-02 2020-12-01 Altimmune Uk Limited Immunogenic compound

Also Published As

Publication number Publication date
BR0214566A (en) 2005-11-01
US20030199538A1 (en) 2003-10-23
HK1073778A1 (en) 2005-10-21
US20080275077A1 (en) 2008-11-06
MXPA04005023A (en) 2004-08-11
PL210514B1 (en) 2012-01-31
KR20040062974A (en) 2004-07-09
CA2467828A1 (en) 2003-06-05
RU2327460C2 (en) 2008-06-27
RU2004116474A (en) 2005-06-10
IL161786A (en) 2012-02-29
US7968562B2 (en) 2011-06-28
JP2005510540A (en) 2005-04-21
AU2002363954A1 (en) 2003-06-10
IL161786A0 (en) 2005-11-20
NZ532769A (en) 2005-12-23
PL373303A1 (en) 2005-08-22
EP1450804B9 (en) 2009-04-01
EP1450804A1 (en) 2004-09-01
KR100962751B1 (en) 2010-06-09
ATE406164T1 (en) 2008-09-15
ES2312659T3 (en) 2009-03-01
DK1450804T3 (en) 2009-01-05
HRP20040474B1 (en) 2014-08-15
AU2002363954B2 (en) 2008-04-03
CN1610550A (en) 2005-04-27
HRP20040474A2 (en) 2004-12-31
JP4447914B2 (en) 2010-04-07
EP1450804B1 (en) 2008-08-27
CN100473384C (en) 2009-04-01
CA2467828C (en) 2011-10-04
DE60228611D1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
AU2002363954B2 (en) Pharmaceutical formulations comprising an immune response modifier
US7915279B2 (en) Method of treating mollescum contagiosum

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 161786

Country of ref document: IL

Ref document number: 2002363954

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 532769

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2467828

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002798470

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500712

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 373303

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/005023

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: P20040474A

Country of ref document: HR

Ref document number: 1168/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 20028237056

Country of ref document: CN

Ref document number: 1020047008119

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003546893

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004/05147

Country of ref document: ZA

Ref document number: 200405147

Country of ref document: ZA

WWP Wipo information: published in national office

Ref document number: 2002798470

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0214566

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 532769

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 532769

Country of ref document: NZ